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This thesis comprises two separate molecular studies on Hereditary Haemorrhagic
Telangiectasia (HHT) families with pulmonary arteriovenous malformations
(PAVMs).
PAVMs occur in over 25% of patients with the autosomal dominant disorder HHT.
They account for some of the most devastating consequences of the disease.
Mutations in two genes, endoglin and ALK1, are known to cause HHT. Both encode
a protein expressed on vascular epithelial cells and are involved in signalling by
members of the transforming growth factor (TGF)(3 superfamily. To date, PAVMs
have not been detected inALK1 families. It has been suggested therefore that
clinical screening for PAVMs is restricted to endoglin-linked families. There is
evidence from a single HHT family without pulmonary involvement that a third
HHT gene may exist.
In one study in this thesis the endoglin promoter region was screened for mutations
in four endoglin-linked families, and four other small families, in whom no
mutations had previously been found studying all coding regions and splice sites of
the gene. No mutations were found. However a two base pair CA deletion
polymorphism, with an allelic frequency of 9% in the UK population, was found
2563 base pairs upstream of one of the major endoglin transcription start sites. It
may prove a useful tool for association studies.
In the other study linkage analyses were performed on four PAVM-HHT families,
two ofwhich were expanded during this study. They had all previously been found
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identification of the gene and elucidation of its biochemical role. It seems reasonable
to speculate that it will encode another component of the TGFP signalling complex
or a downstream effector, and so its identification should increase our understanding
of this superfamily of signalling molecules. Further work however is still required to
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The classical patient with HHT has epistaxis, telangiectasia around the lips and
finger tips, and a similarly affected relative. However several other organs may also
be involved accounting for some of the more devastating clinical complications of
the disease. The manifestations are all due to abnormalities of vascular structure.
Mutations in two genes, endoglin and ALK1, are known to cause HHT. They both
encode cell-surface proteins involved in signalling by the TGFp superfamily. To
date, PAVMs have not been detected in ALKl-Mvksd families. There is evidence




Recurrent epistaxis, often associated with haemoptysis and occurring in several
family members, was first noted by Sutton in 1864'. A hereditary tendency to
epistaxis was confirmed one year later by Babington^. The first report of skin
lesions being associated with hereditary epistaxis was made in 1876 by Legg. His
contribution was overlooked, as he suggested that the features were associated with
haemophilia and described the skin lesions too imprecisely as "naevi"3. The naevi
were redefined as telangiectases by Chiari in 1887 but haemophilia continued to be
diagnosed^. Rendu, in 1896, distinguished this disease from haemophilia, by the
lack of haemorrhage from skin lacerations and tooth extractions^. He also discussed
associated gastrointestinal bleeding. The disease was brought to proper attention by
Osier in 1901 who gave a classic description of the characteristic triad of recurrent
epistaxis, hereditary pattern, and multiple cutaneous telangiectases^. This provoked
several other reports of telangiectasia with epistaxis^-10 but it was Weber in 1907
who most clearly further defined its clinical manifestations and behaviour1 1 leading,
possibly unfairly, to the eponymous name Rendu-Osler-Weber syndrome. Hanes, in
1909, most clearly described the inheritance pattern of the disease, described the
appearance of telangiectases under the light microscope, and gave the disease the
name Hereditary Haemorrhagic Telangiectasia (HHT)12
The existence of pulmonary capillaries was first described in 1661 by Malpighus^.
Churton in 1897 described abnormalities of the pulmonary vasculature in the form of
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"aneurysms as large as walnuts" in a boy who had haemoptysis and epistaxis'4.
Pulmonary arteriovenous fistula was described in 1939 by Smith and Horton' 5
Rundles in 1945 described a pulmonary artery aneurysm in an HHT patient who also
had gastric telangiectasia' 6 Gastric telangiectasia had been previously described by
Renshaw in 1936'7. In 1947, Whitaker postulated that cyanosis associated with
"cavernous haemangioma of the lung" is due to its shunt effect
1.1.2. EPIDEMIOLOGY
HHT occurs with a wide geographic distribution among many ethnic and racial
groups including negro Americans'9 20^ Mexicans^', Chinese^ Indians^ Thai'24?
and Japanese^^. Studies of prevalence give varying figures of 1 in 2351 in the
French region ofAin^65 l in 3500 on the Danish island ofFunen^?, 1 in 5155 in the
Dutch Leeward Islands^, 1 in 16,500 in Vermont^ and 1 in 39,216 in northern
England although this is thought to be almost certainly an underestimate^". These
figures, and others recently published^', show that, at least in the population
investigated, HHT is more prevalent than previously thought, at around 1 in 10,000.
Figures of around 1 in 100,000 had been formerly reported^ 33
The disease is autosomal dominant with an estimated penetrance overall of 97%30
34. This, however, is age-related with manifestations developing throughout life34
35 and varying between affected individuals even from the same family36 37 There
are very few reports of homozygous cases38 39 m one 0fwhom the condition was
fatal. Thus affected individuals are almost exclusively heterozygous.
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1.1.3. VASCULAR STRUCTURE
An AVM consists of a dilated aneurysmal sac of arterial and venous origin supplied
by one or more feeding arteries and draining to one or more dilated veins. There is
no intervening capillary bed40(see Figure 1.1). 95% ofPAVMs derive their arterial
supply from the pulmonary rather than the systemic circulation^!. Telangiectases
are also abnormal vascular structures but instead are due to dilated arterioles,
capillaries and postcapillary venules42-44
1.1.4. CLINICAL FEATURES
1.1.4.1. NOSE
Spontaneous, recurrent nose bleeds from telangiectases of the nasal mucosa is the
most common clinical manifestation ofHHT. It occurs in more than 90% ofaffected
individuals^ beginning by the age of 10 years in many and the age of 21 years in
most45. Controversy exists regarding the progression of epistaxis with age. Some46
have demonstrated that it remains stable over time, McCaffrey et al have shown a
group with 25% progressive, 45% static, and 17% regressive symptoms^ and some
have found that it tends to be progressive in the majority34 45 48 xhe severity is
very variable between individuals. A mortality rate of up to 4% has been quoted^
although no recent data is available.
Many require no treatment. Others may require nasal packing, multiple transfusions,
and oral iron supplementation. Many other more definitive treatments have been
tried. Argon and ND Yag laser treatment has a beneficial effect but data on long
tenn effects is scarce^® 51 Septal dermoplasty in adept hands has good results in
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patients with severe epistaxis but vessels usually regrow^ 53 Oral high dose
oestrogen therapy (1 -5mg oestradiol/day) has been tried. Oestrogens appear to be
effective in uncontrolled studies^ but controlled studies do not support efficacy^
55. The possible complications of long term oestrogen must also be considered"^.
Nevertheless oestrogen and progesterone receptors have been shown to be present in
nasal telangiectases in females (progesterone receptors only in males) compared to
none in normal controls56. The mechanism of any possible action remains unclear,
but it has been suggested that oestrogens improve continuity of telangiectatic
endothelium and so decrease bleeding tendency^ or they may act by inducing
squamous metaplasia^. Transcatheter embolotherapy of arteries leading to the nasal
mucosa has been tried. Older studies indicate it may be less effective in HHT
patients than other individuals57-59^ but there are no data regarding results using
more modern methods.
1.1.4.2. SKIN AND BUCCAL MUCOSA
Telangiectases of the skin and buccal mucosa occur in about 75% of individuals^
(see Figure 1.2) typically presenting later in life than epistaxis^^ from about the third
decade of life49 and increasing in size and number with age^O 61 They mostly
occur on the face, lips, tongue and buccal mucosa, and fingertips, but can occur
elsewhere. They may bleed (bleeding from conjunctival telangiectasia causes
"bloody tears" but this is rarely clinically important^). The main concern is
cosmetic. Laser ablation can be used^T
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1.1.4.3. GASTROINTESTINAL TRACT
Recurrent haemorrhage of the gastrointestinal (GI) tract occurs in a substantial
minority (up to 44%) ofHHT affected individuals?? 34 64 ancj js the second most
frequent site of haemorrhage^, it often presents as an iron deficiency anaemia but
occasionally as an acute GI haemorrhage??. The onset is usually from the fifth or
sixth decade^4 in half the patients the site ofbleeding is telangiectases in the
stomach or duodenum. Far fewer have blood loss due to colonic telangiectasia?? 64
65. They are visualised by endoscopy and are similar in size and appearance to
mucocutaneous telangiectases but may be surrounded by an anaemic halo??. Less
commonly arteriovenous malformations (AVMs) and aneurysms may occur, depicted
by GI angiography64 66 Most patients are satisfactorily managed conservatively
with, if necessary, blood transfusions or oral iron therapy64. However laser therapy
may also be used to control bleeding in the short term, but less commonly in the long
term65 67 Recurrence of bleeding is very common, due to missed or incompletely
treated lesions or recurrent disease6?. Immediate or delayed haemorrhage from the
laser treatment, or perforation, may occur68. A low dose combination of oestrogen
(0.05mg oestradiol/day (a "high contraceptive dose")) and progesterone has been
shown to be beneficial in controlling severe blood loss through GI telangiectasia, and
for the effect to remain for several months after cessation of treatment69. The mode
of this effect has yet to be determined69. Effectiveness of treatment with
aminocaproic acid (antifibrinolytic) has been found to be variable?® ?1. Surgery has
limited success due to recurrent disease6?.
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1.1.4.4. HEPATIC
Hepatic involvement may occur in up to 30% ofHHT patients22. Large
arteriovenous malformations (AVMs) may occur between the hepatic artery and vein
and can result in a substantial left to right shunt^ 74 pr0yen by a higher oxygen
saturation in the hepatic vein than the inferior vena cava74 This may give rise to
high output cardiac failure^. Shunts between the hepatic artery and portal vein
occur more rarely and lead to hepatic encephalopathy^ particularly after G1 tract
bleeding. They can also lead to portal hypertension with associated oesophageal
varices^. Ascites has been reported in association with multiple AVMs but no
portal hypertension77. Spontaneous bleeding from liver AVMs has not been
reported. AVMs can occur alone or in combination with fibrosis of the liver78
Linkage of fibrous bands results in nodularity of the hepatic parenchyma but without
disruption of the architecture within the nodules as in true cirrhosis^ 79 This is
known as "cirrhosis ofHHT". The clinical significance of this is debated^. True
cirrhosis can also occur either due to coexisting disease, for instance cardiac failure
or alcoholism, or due to treatment for HHT symptoms, for example massive blood
transfusion or long term oestrogen treatment. 80. Hepatic AVMs, suspected by
hepatomegaly, a liver bruit, and sometimes raised yGT and alkaline phosphatase
levels'^ can be diagnosed by angiography, CT, MRI, or doppler sonography22 74
81. Doppler sonography has been suggested to be the ideal method for screening^2
although screening is not performed in the U.K. Treatment ofAVMs is largely
conservative^. Embolisation of feeding vessels is performed73 but a 25% mortality
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rate was calculated in 1996 from all the data available ^2 Liver transplantation may
be necessary if disease is extensive*^. Following several cases of fatal hepatic
necrosis occurring after hepatic embolisation, the United States FIHT physicians have
placed a moratorium on embolisation of hepatic AVMs where portal shunting cannot
be definitely excluded, unless supported by hepatic transplantation*^.
1.1.4.5. URINARY SYSTEM
Involvement of this system is rare (0.6%)34. Telangiectasia can occur over the
bladder and urethra*^. Treatment other than iron therapy is rarely required*^.
1.1.4.6. CEREBRAL
5-10% ofHHT patients are thought to have cerebral involvement^ 86 with
telangiectases, AVMs (cerebral AVMs (CAVMs)), aneurysms, or cavernous
angiomas*^ (See Figure 1.3). However screening of asymptomatic patients indicates
a higher incidence*^. jn a literature review of 77 cases of cerebral involvement,
47% had telangiectases, 22% CAVMs, 8% aneurysms, and 22% spinal vascular
malformations*^. Most complications arise from CAVMs. They can lead to
headache, seizures, ischaemia of the surrounding tissue due to a steal effect, or
haemorrhage*^. it is unclear whether the natural course ofCAVMs in HHT is the
same as for CAVMs unassociated with HHT, in whom the average yearly bleeding
risk is between 2 and 3%****, but it is usually assumed to be the same. The
haemorrhage risk of a CAVM has been found to vary with certain features of the
lesion: small size ofCAVM***>, deep venous drainage, feeding by perforators,
intranidal aneurysm(s), multiple aneurysms, feeding by the vertebrobasilar system,
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and location in the basal ganglia have been found to increase the risk of
haemorrhage^^. Overall a haemorrhage risk of 2% per annum^ 90 js usecj as the
basis of risk-benefit analyses when screening is contemplated. Analyses suggest that
in asymptomatic patients the risks of haemorrhage with expectant treatment
outweigh the risk of intervention, particularly in young patients^!. However patient
age, specific features of the lesion, and available expertise must be considered for
each individual^!. Although screening is offered in USA and Canada, it is not yet
offered in Europe and the question of whether it should be remains the subject of
intense debate.
In order to justify a prospective study to establish the value ofCAVM screening and
treatment in asymptomatic HHT patients, particularly in younger groups, in the UK,
a series of 80 HHT families identified by at least one individual from each presenting
to the Hammersmith Hospital was studied by myself and Dr Shovlin. Full family
histories revealed that out of 335 individuals, from these 80 families, 25 (7.5%)
suffered catastrophic cerebral haemorrhages (almost all fatal or leaving severe
residual impairment) with many of the haemorrhages being due to CAVMs and 7 of
the patients being aged between 10 and 22^2. The proposed study therefore seems
appropriate.
The best diagnostic approach varies with the different lesions. Telangiectases can
only be detected by MRI^. MRI is also the best method for detecting cavernous
haemangiomas93. MRI and angiography are more sensitive than CT in detecting
CAVMs^2? but significant procedural morbidity and exposure to radiation and IV
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contrast with angiography makes this unsuitable as a screening procedure. IV digital
subtraction angiography avoids this but the resolution is low and vertebrobasilar
system poorly visualised^. Therefore MRI seems to be the best technique for
screening*^. It should be noted however that MRI should not be performed in
PAVM patients embolised with non-MRI compatible coils. This accounts for the
majority of patients who were embolised before the late 1990s.
The method of treatment depends on site and type of lesion, availability, and local
expertise. Surgery, embolisation, and stereotactic radiotherapy can be used alone or
in combination^. A comparison of series of patients, treated by stereotactic
radiotherapy or microsurgery, indicates that stereotactic radiotherapy is less
efficacious and has a higher associated morbidity and mortality than microsurgery94
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1.2. PULMONARY ARTERIOVENOUS MALFORMATIONS
Further information can be found in an extensive recent review of pulmonary
arteriovenous malformations in HHT^.
1.2.1. EPIDEMIOLOGY AND PRESENTATION
Involvement of the lungs, in the form of pulmonary arteriovenous malformations
(PAVMs), occurs in 15-33% ofHHT patients^ 86 96 Onset is in the relatively
young (20% ofPAVMs in those under 20 years, 50% in those under 38 years in one
series^). At least 70% of all PAVMs occur in HHT patients and so the possibility
ofHHT should be considered in anyone found to have a PAVM^? 98 This is
particularly so if there are multiple lesions which are especially common in HHT
patients97-T00 70% ofPAVMs are localised in the lower lung fields97 100 101
PAVMs usually increase in size96 98 101 ^ particularly if they are multiple^!, and
very rarely regress96 Complications from the PAVMs are more common in HHT
than non HHT patients99 102 Mortality rates for untreated PAVM patients range
from 4-22%99-101 103 This may be due to PAVMs haemorrhaging into a
bronchus or the pleural cavity!94-106 causing haemoptysis (11% on average) and
haemothorax (less than 1% on average) respectively95. The more common
complications ofPAVMs however arise from the right to left shunts resulting from
the capillary-free communications between pulmonary and systemic circulations.
Critically, paradoxical embolism can occur through these shunts due to material
which is normally trapped by the small diameter capillaries being able to pass
through the wider PAVMs. This may lead to transient ischaemic attacks (TIAs) or
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cerebrovascular accidents (CVAs) in, on average, 24%, and cerebral abscesses in, on
average, 9% ofPAVM patients 95 More rarely other systemic emboli may occur
for instance to the kidneys or knee joints197 PAVMs in fact account for two thirds
of all neurological symptoms in HHT patients^?. A high incidence ofmigraine, in
43% ofHHT patients with PAVMs, has been reported but the underlying reason not
elucidated1^. This has not however been found by others and the data presented in
this thesis does not support this finding (see Sections 4.1.1 and 4.2.1). Hypoxaemia
occurs due to the shunted blood avoiding oxygenation. It is often well tolerated due
to generation of a high cardiac output, facilitated by low pulmonary vascular
resistance 198 p does, however, present as dyspnoea on exertion in, on average
47%, and chest pain (due to associated polycythaemia as well as hypoxia) in 12%95.
Central cyanosis, clubbing, or a vascular bruit are present in, on average, 30%, 36%,
and 49% respectively ofPAVM patients'^. Up to 50% of patients with these signs
or an abnormal chest x-ray have no respiratory symptoms^ and for many of them
the first presentation of lung involvement is with a neurological event99 100 ] 3%
ofPAVM patients in fact die from fatal CVAs99 100 As treatment for PAVMs is
successful 199 screening for them prior to these catastrophic events is vital.
1.2.2. DIAGNOSIS
It is recommended that PAVM screening is performed every 5-10 years36 82 or
around pregnancy and puberty since these are associated with PAVM
enlargement196 110 All genotypes should be screened (see Section 5.2.3). Current
recommendations for investigation ofPAVMs vary for individuals suspected of
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having them through clinical features or screening investigation. One
recommendation is to perform a PA and lateral CXR, arterial blood gas (ABG)
analysis and/or supine and erect oximetry. If these raise concern at least one non¬
invasive further investigation is recommended before pulmonary angiography is
considered^. Alternative strategies used in different institutions include use of
contrast echocardiography as an initial screen ''', arterial blood oxygen levels rather
than oximetry86, measurement of the right to left shunt breathing 100% oxygen86;
and more extensive use ofCT scanning! 12
1.2.2.1. OXYGEN SATURATION
As mentioned in Section 1.2.1, PAVMs lead to hypoxaemia due to the anatomic
right-to-left shunt provided by the abnormal vessels which bypass the pulmonary
capillary bed. The simplest method for detecting a right-to-left shunt is the
demonstration of a low partial pressure of oxygen (Pa02) in arterial blood by blood
gas analysis. The detection of hypoxaemia alone using age-defined Pa02
[104mmHg-0.24 x age] has been used as a single diagnostic test86? but the
differential diagnosis of hypoxaemia is wide and this results in low sensitivity
(66.7%) and specificity (60.7%). The oxygen saturation (Sa02) derived from pulse
oximetry has been investigated as a potential test in view of simplicity and patient
comfort, particularly for recurrent evaluations. The bias and precision of pulse
oximeters has been found to compare favourably with conventional arterial blood
samples for oxygen saturations of 80% and above'' 3 Data on reproducibility in
nonnal subjects suggest a change of 1% in oxygen saturation above 90% and 2% in
oxygen saturation below 90%, using pulse and conventional oximeters, indicates
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clinical change has occurred 113 This has been further validated in a PAVM
population by an institution using Biomeda oximeters, taking the mean of 10 values
obtained at one minute intervals 114. In these authors' hands, Sa02 in the erect
posture of< 96% gave a sensitivity of 73% and specificity of 35%, and < 97% gave a
sensitivity of 100% and specificity of 10%, for detection ofPAVMs as defined by
selective pulmonary angiography. Their erect Sa02 was a better predictor of disease
than supine saturations. This reflects the preponderance ofPAVMs in the lung bases
leading to increased shunting in the erect posture due to gravitational pooling of
blood 113. This study also addressed whether the fall in oxygen saturation on
assuming the upright posture, orthodeoxia, could be useful. Although this was no
better a predictor ofPAVM disease than erect Sa02 alone, the study demonstrated
that the supine-erect Sa02 was significantly greater in the PAVM rather than non-
PAVM group: 1.7% (SD 2.7) compared to 0.3% (SD1.5) p=0.01114. Erect oxygen
saturation and orthodeoxia measured by pulse oximetry are therefore published
methods of identifying individuals requiring further investigation for possible
PAVMs but are not complete diagnostic investigations, due to insufficient sensitivity
and specificity*^.
1.2.2.2. CHEST X-RAY
Chest X-ray (CXR) has also been suggested as a screening investigation since 40-
83% ofPAVMs are revealed by CXR when interpreted by experienced radiologists
with a high index of clinical suspicion*^ 98 101 111 116 (see Figure 1.4) . However
there is a lack of specificity^ 1^1 and insufficient sensitivity, even when lateral
CXR is used in addition to posteroanterior (PA) CXR, particularly for small or
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diffuse PAVMs 116 It is reported to be better than oxygen saturation for
detecting PAVMs which are large enough to embolise^. it is important to
determine therefore the clinical significance ofPAVMs smaller than this (see Section
5.1.2).
1.2.2.3. THORACIC CT SCANNING
Thoracic CT scans can detect small as well as large lesions and identifies thrombosed
and recanalised structures. Exposure to radiation and a lack of specificity are
problems^ 12 117 (see Figure 15) Helical scans with 1mm slices at 5mm intervals
had 98.2% sensitivity, compared to pulmonary angiography, for detecting PAVMs in
one series 112.
1.2.2.4. INTRAPULMONARY SHUNT INVESTIGATIONS
Intrapulmonary shunts can be detected using the 100% inspired oxygen breathing
method, radionuclide scanning using technetium 99m labelled albumin
macroaggregates or microspheres, or by contrast echocardiography.
Some have found that results obtained with the 100% oxygen breathing method and
radionuclide scanning are similarl 18. Others however have found that 100% oxygen
breathing tends to underestimate the shunt probably as the "driving pressure" for
oxygen diffusion is increased due to a much higher partial pressure of oxygen in the
alveoli when breathing 100% oxygen rather than room airl 19. Recently radionuclide
shunting ofmore than 3.5% has been found to have 87% sensitivity and 61%
specificity for detecting PAVMs compared to pulmonary angiography, the "gold
standard"! 14. Comparable figures, allowing for differences in patient selection,
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exist for 100% oxygen breathing^. The debate about which method is better
therefore continues.
Contrast echocardiography utilises the fact that with an intracardiac shunt
microbubbles are seen almost immediately in the left ventricle whereas with an
intrapulmonary right to left shunt there is a 2-5 second delay'20. it has been found
to be suggestive of intrapulmonary shunt in patients who have no PAVMs on
pulmonary angiography- in 40% of patients in one series 1 ". It is not clear yet what
the clinical relevance is of shunts detected by contrast echocardiography but not seen
at pulmonary angiography^.
1.2.2.5. PULMONARY ANGIOGRAPHY
This is still the gold standard investigation and is used as part of the therapeutic
embolisation procedure (see Figure 1.6). It should be performed in all patients in
whom clinical data and CT scanning or shunt measurements are highly suggestive of
the presence ofPAVMs^. Despite pulmonary angiography being the gold standard,
it can fail to detect PAVMs identified by CT scanning and shunt investigations,
particularly contrast echocardiography^^ 111 112 [t js thought that this is due to
these lesions being too small for detection'21 since the abnormal shunts persist after
apparently successful embolisation in about 60-75% ofPAVM patients' '4 '22 The




Embolisation has now replaced surgery as the mainstay of treatment as it allows
parenchymal sparing, which is particularly important as the disease is often recurrent.
There is also a lower procedural morbidity. It is performed at the time of pulmonary
angiography by positioning either a detachable balloon or coil in the vessel leading to
the PAVM (see Figure 1.6)95. pAVMs with a feeding vessel of 3 mm or more in
diameter are amenable to embolisation121. Thrombus then forms around the device.
In the majority of patients it is efficacious, in terms of shunt measurement, although
is operator dependent, requiring a highly skilled radiologist^. Recurrence of
PAVMs occurs either due to recanalisation of original PAVMs through poorly
occluded vessels, or due to new pulmonary or systemic feeding vessels supplying the
original PAVM10^ or because of new PAVMs forming due to the recurrent nature
of the disease, particularly likely with the removal of a low resistance shunt95.
Patients therefore require follow up after a few months and often several treatments
are needed^ 122 123
Both balloons and coils must be small enough so that they can be placed sufficiently
distally, thereby avoiding occlusion of a vessel leading to a normal capillary,
otherwise pleurisy due to pulmonary infarction would occur. It is argued that
balloons are less likely to cause this^? but around 10% of patients were found to
develop pleurisy in 3 series, 2 using coils and 1 using balloons^? 102 122 They
must not be too small however otherwise they may embolise through the PAVM
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themselves 107 122 123 other complications that may arise include paradoxical
embolism, angina and cardiac arrhythmias due to air embolism^ and
postembolisation haemothorax^S. After treatment of a PAVM, pulmonary
hypertension and right heart failure due to high cardiac output from a coexistent
hepatic AVM may be unmasked by removal of the low resistance shunt 107 123
Embolisation of vessels less than 3 mm in diameter has been attempted with more
difficulty^. in one study patients with diffuse PAVMs showed no significant
change in hypoxia after embolisation of large PAVMs and 5 episodes ofCVA/TIA
occurred in the 12 treated patients 124 This, along with data presented in this thesis
(see Section 4.1.1.2), suggests that microscopic PAVMs are clinically relevant, but
further data is required.
1.2.3.2. SURGERY
PAVMs occur subpleurally in more than half of patients and so are amenable to
video-assisted thoracoscopic wedge excision of the PAVM. This reduces the
complications of surgery 125 Bilateral lung transplantation for diffuse PAVMs in a
patient without HHT has been described as being successful in that ABGs and a 6
minute walk test were normal 8 months after transplantation 126 However long term
follow up in this case is not known. In patients with diffuse disease it is suggested
that the 2 year survival rate is poorer in those treated by lung transplantation than
those treated conservatively 124.
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1.2.3.3. ANTIBIOTICS
Prophylactic antibiotic therapy prior to undergoing procedures that can evoke
bacteraemia is recommended in all those suspected of having PAVMs'27. jn view
of concern over the significance ofmicroscopic PAVMs this is being extended to
include those in whom PAVMs have been treated unless they are one of the few in
whom no residual shunts remain^.
1.2.4. PREGNANCY AND OESTROGEN
The majority ofwomen who are going to develop HHT have done so by the time
they reach child-bearing age^5. Pregnancy tends to exacerbate HHT manifestations,
in particular pulmonary haemorrhage and complications due to shunting through
PAVMs 106s but deterioration is also seen in hepatic, cerebral, and mucocutaneous
vascular beds'06 128 Various mechanisms are postulated for the deterioration. The
increased cardiac output and vascular volume '29 may precipitate haemorrhage from
abnormal vasculature'06. An alternative possibility is that the associated fall in
systemic and pulmonary vascular resistance'29 may accelerate the dilation of
existing lesions or precipitate their initial production'06 The latter mechanism
would account for the majority of the complications seen.
In addition to the change in haemodynamic state during pregnancy potentially
altering the course of the disease, there may also be a localised hormonal influence
on the vessels. Oestrogen secretion increases markedly during pregnancy such that
towards the end of pregnancy the equivalent of 20mg oestradiol/day is produced' 30
Very high levels and very low levels of oestrogen have been shown to worsen HHT.
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Very low levels (<50micrograms of oestradiol equivalent per day) are thought to
account for worsening of epistaxis in HHT patients during the low oestrogen states of
the 5 days in the menstrual cycle prior to menstruation, the menopause^ 131 after
oovarectomyl31; and on the low dose oestrogen oral contraceptive pill 132 Very
high levels of oestrogens (20mgs/day) are postulated as accounting for the increased
frequency ofPAVMs in females ! and possibly the worsening ofPAVMs during
pregnancy 1^6 jn Spjte of these findings, there is evidence that an intermediate dose
of oestrogen at a "high contraceptive dose" of 50micrograms oestradiol/day is
definitely beneficial for HHT associated GI bleeding69 and doses of up to 5mg
oestradiol/day may be efficacious for HHT associated epistaxis43 48 56
The mechanisms by which oestrogens have these effects are likely to vary according
to dose. The benefits of high dose oestrogens in management of epistaxis has been
ascribed to alterations in the vascular wall by induction of squamous metaplasia (see
Section 1.1.4.1). This mechanism could not be responsible for the improvement in
gastrointestinal bleeding at lower doses. Possible alternative explanations might
include upregulation of transcription from the remaining endoglin gene in endoglin-
deficient HHT patients (three oestrogen response elements have been identified in
the endoglin promoter!33a shift towards a prothrombotic tendency!34, or indirect
effects on vascular function.
1.2.4.1. IMPLICATIONS FOR MANAGEMENT OF HHT PATIENTS
The current recommendations arising from these considerations are two-fold. First,
the van Cutsem^9 dose of female hormones (50microgram ethinyloestradiol, lmg
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progesterone) is used to treat transfusion-dependent patients with gastrointestinal
bleeding. More relevant to this study is the recommendation that, recognising the
potential risk of pregnancy, whether or not it is due to the high oestrogen state,
women should be screened for PAVMs ideally prior to, and, if necessary, during
pregnancy. Physiological changes in pregnancy may mask hypoxaemia due to
PAVMs (an elevation in the mixed venous oxygen content results from the elevated
cardiac output and progesterone stimulation of the respiratory centre) and
rescreening soon after delivery is warranted^. Embolisation is safe up to and
including the third trimester '05.
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1.3. GENETICS OF HHT
Knowledge of the genetics ofHHT is enabling understanding not only of the
mechanisms underlying HHT but also, more broadly, those involved in vascular
development and homeostasis generally, with far reaching clinical implications in
many disease processes. It also establishes whether or not there is any correlation
between HHT genotype and phenotype which would have important implications for
clinical screening and prognosis.
HHT is known to result from mutations in two genes. An HHT locus, HHT1, was
assigned by linkage studies to chromosome 9^5 135 The disease gene was later
identified as endoglin^6. The initial chromosome 9 linkage studies indicated that a
further gene existed^ and later a second HHT locus, HHT2, was mapped to
chromosome 12^7 138 The mutated gene was ascertained to be ALK1 1 39 The
existence of a third gene was suggested by linkage studies on one HHT family with
extensive hepatic but no pulmonary involvement. This pedigree was unlinked to
both endoglin and ALK1. The locus and gene have not been identified to date 140
1.3.1. PHENOTYPE-GENOTYPE CORRELATIONS
Could there be any correlation between phenotype and genotype? Several reports
suggested that PAVMs only occurred in endoglin-XivkQd families and not in those
unlinked to endoglin^ 1 142 The implication of this would be that only endoglin
families need to be screened for PAVMs. However although PAVMs are
significantly more common in endoglin-livked families^ 143 144 they do not occur
exclusively in them^S 37 The family found to be unlinked to endoglin and ALK1
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had no pulmonary involvement 140 However this is evidence from only one family
and, as will be shown, my data shows otherwise. Moreover affected individuals in
the same family can have very differing severities of disease so it is difficult to make
a prognosis about the course of disease in any individual^ 37
1.3.2. ENDOGLIN
The endoglin gene lies on the long arm of chromosome 9 35 135 vari0us mutations
including deletions and insertions, missense mutations and point mutations
generating premature stop codons, have been identified 37 136 145-148 Almost all
mutations have been found to be unique to a particular family37 136 145-148 making
mutational screening programmes problematic. In some e«£/og/m-linked families no
mutations have been found, studying all coding regions and splice sites of the
gene37. With the apparent clustering of premature termination mutations, it was
hypothesised that a truncated protein is translated which disrupts normal endoglin
function via a dominant-negative effect 145. However the identification ofmissense,
frameshift, and nonsense mutations which all lead to very low or undetectable levels
ofmessenger RNA transcripts suggested the prevailing nature of the mutations is to
create a null (nonfunctional) allele37 148_ haploinsufficiency model.
Furthermore when mutant proteins are translated they only exist transiently within
the cell, not reaching the cell surface 146 The haploinsufficiency model is now
widely accepted as the mechanism by which these mutations act' 49
This haploinsufficiency model has been further confirmed by a recent murine model
ofHHTl50 where manifestations ofHHT were seen in some mice expressing a
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single copy of the endoglin gene. Previously embryonic lethality at gestational day
11.5 in mice completely lacking in endoglin, i.e. homozygous endoglin null mice, of
129/SvJ embryonic stem (ES) cell origin, was shown to occur due to defective
vascular development^'. Lethality in endoglin null mice was also shown in ref.' 50
again due to defects in angiogenesis and also abnormalities in heart development. In
these mice (129/Ola ES mice bred into C57BL/6 mice), however, death occurred at
gestational age 10-10.5 days suggesting that phenotypic differences between
endoglin null mice of different genetic backgrounds may be due to modifier genes
and/or epigenetic factors. The role ofmodifier genes and epigenetic factors was
further suggested when observing the heterozygous mice 150 where the variability of
organs affected, age of onset, and severity of disease was noted both between mice of
different genetic backgrounds (129/Ola mice were most severely affected) and
between mice of the same genetic background. This parallels human HHT and is
thus an elegant and potentially extremely useful HHT model.
Endoglin (CD 105) is predominantly expressed on all types of vascular endothelium
and is recognised as an endothelial cell marker! 52 it is also expressed on the
syncytiotrophoblast (responsible for hormone synthesis and nutrient exchange) of the
placenta^ 53^ fibroblasts 154 155^ sm0oth muscle cells 156^ transiently on endocardial
cushion tissue mesenchyme during heart septation and valve formation! 50 157, pre-
erythroblastic bonemarrow mononuclear cells 158, activated macrophages 159 (it is
upregulated on these compared to peripheral monocytes)!59. it is upregulated on
endothelial cells in tumour vasculature160, inflamed tissues including skin lesions
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e.g. psoriasis 160 161 jn response to ionising irradiation162? ancj jn fibroblasts in
pulmonary fibrosis163
The haploinsufficiency model allows screening for possible HHT1 patients to be
performed by measuring the level of endoglin expressed on peripheral blood
activated monocytes and umbilical vein endothelial cells. In the U.K., in contrast to
the United States and Canada, ethical approval has not been granted for screening of
newborns by measuring endoglin expressed on umbilical vein endothelial cells.
HHT1 patients have decreased endoglin levels whereas HHT2 patients and
unaffected individuals have normal levels of endoglin^.
It had been suggested that endoglin mutations were loss-of-function alleles requiring
somatic inactivation of the normal allele for vascular lesion development, in other
words a two hit phenomenon similar to that hypothesised for tumour suppresser
genes^6 However reduced levels of endoglin are also seen on the endothelial cells
of apparently normal vessels ofHHT1 patients compared to the levels seen in
unaffected individuals and also compared to the normal levels of endothelial cell
marker, PECAM1, in HHT patients 164 The same levels are also seen in abnormal
vessels making it unlikely that the theory is correct that AVMs occur when the
normal copy of the endoglin gene is inactivated by a second hit *64
1.3.3. ENDOGLIN PROMOTER
The promoter region of human endoglin was recently cloned and characterised133
The relevant elements that participate in endoglin transcription were determined by
comparing the activities of a series of endoglin promoter fragments. The fragments
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were inserted into a reporter vector containing the luciferase gene. BAEC (bovine
aortic endothelial cells) were transiently transfected with the constructs and
luciferase activity measured. The largest construct, -851/+350, i.e. spanning from
851 base pairs upstream of one of the major transcription start sites to 350 base pairs
downstream of it, had similar activities to its -400/+341 and -224/+341 derivatives
(about 700 fold increase over a promoterless vector). However the construct -851/-
400 showed no promoter activity and plasmids -141/+341 and -81/+350 showed a
decreased level of activity compared to —400/+341 and -224/+341. This suggests
that the region 81 base pairs upstream of the transcription start site can act as a basal
promoter with additional regulatory elements in the 319 base pair fragment
immediately 5' of this required for optimal transcription. An Alu sequence, often
located upstream of regular transcription units, was found at -927/-666 supporting
the view that the major transcription regulatory element was downstream of this.
Many transcriptional start sites have been identified within the -400/+341 fragment.
Unusually no consensus TATA or CAAT boxes have been found but instead guanine
and cytosine (GC) rich boxes at—47/-29 and -5/+16 have been found along with an
Spl binding site at -37. These are a feature of TATA-less genes which have
multiple transcription start sites 165 The lack ofTATA and CAAT boxes is a
common feature in components of the TGFp superfamily^ 66-170
Several potential transcription factor binding sites, also present in other endothelial
gene promoters, have been identified. These include NFkB, GATA, AP2, Spl, and
ets and all lie within the 741 base pair fragment. Interestingly NFkB sequences are
responsive to mechanical forces, by regulating shear stress response element-
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dependent gene expression^!, which could account for a potential role in regulating
endoglin transcription when endothelial cells are subjected to haemodynamic forces
of the bloodstream, similar to mechanisms occurring in other endothelial genes!^!.
GATA and ets are seen in other endothelial genes and, more specifically, AP2 and
Spl sites are present in promoters of other components of the TGF(3 superfamily
(TGF(31, P3, biglycan (a small proteoglycan which interacts with TGFP), and TGFP
receptor types I and II)! 66 169 170 172-174 ^.n e^s family member also regulates
expression ofTGFp receptor type Il!75.
Other potential TGFp responsive elements were identified within the 741 base pair
fragment including 2 sites for the TGFP-related signalling proteins, Smads, 10 TGFp
activation elements, 6 TGFP control elements, and 2 TGFp inhibitory elements. In
keeping with this, promoter activity was found to be stimulated by TGFpi !33.
Interestingly 3 oestrogen response elements, 1 glucocorticoid response element, and
5 vitamin D response elements were found in this fragment. This could explain, at
least partially, the contrasting effects of low, medium, and high oestrogen states, as
discussed in Section 1.2.4.
It has recently been shown that two of the Smads, Smad3 and Smad4, components of
the downstream signalling pathway for the TGFP superfamily, bind to specific DNA
sequences inducing transcription of downstream target genes. They mimic the
transcriptional effect of TGFP 1 on the plasminogen activator inhibitor 1 (.PAI-1)
promoter (the best characterised TGFpi-inducible promoter). Although specific
Smad-response elements are present in the PAI-1 promoter, interestingly in at least
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one study, mutations which eliminated particular Smad DNA binding sites did not
interfere with TGFpi-dependent or Smad-dependent transcriptional activity.
However both TGFpi-dependent and Smad-dependent transcription was eliminated
by mutation of adjacent API sites'76. It would appear from this that Smads alter
transcription through sequence-specific DNA binding and through potentiating API-
dependent transcription'76 a Smad4 mutation identified in a human pancreatic
carcinoma abolished Smad4 DNA binding activity, preventing transactivation of
TGFp responsive genes. This emphasises the importance of the TGFP superfamily
and Smads in carcinogenesis'77 The finding of two Smad responsive elements in
the endoglin promoter highlights the role of endoglin in TGFp superfamily
signalling.
1.3.4. ALK1
The activin receptor-like kinase (ALK1) gene lies in the pericentromeric region on
the long arm of chromosome 12'37 138 Mutations in this gene, like in endoglin,
appear to be unique to a particular family. They include missense and nonsense
mutations, and deletions and insertions, and are found in sequences encoding the
highly conserved kinase, transmembrane, and extracellular ligand binding domains
139 178 179 Some mutant alleles lead to undetectable or low levels of an unstable
messenger RNA transcript suggesting that haploinsufficiency is occurring here as in
endoglin 178-180
ALK1 is found, like endoglin, predominantly on human endothelial cells and in lung
and placenta'79 181 182 jn the rat it has also been found on splenic macrophages
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and in the bone marrow' 83 The distribution ofALK1 is similar to that of endoglin
and also TGFpl suggesting a close functional association.
As for endoglin, embryonic lethality has been demonstrated in homozygous ALK1
null mice occurring at gestational day 10.5-11.5 due, as in endoglin null mice, to
vascular development abnormalities 180 However, unlike in endoglin null mice, the
mice in ref.' ^0 which were heterozygous for the ALK1 mutation showed no evidence
of the HHT phenotype. It is not clear whether this reflects intrinsic differences with
requirements for human and murine ALK1, or absence of appropriate environmental
triggers in the ALK1 null mice.
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1.4. TGFP: THE ROLE OF ENDOGLIN AND ALK1 IN THE
SUPERFAMILY
The structurally related peptides forming the transforming growth factor (3 (TGFP)
superfamily are factors which play diverse and fundamental roles in growth and
differentiation 184. They include the TGFP isoforms, pi, P2, p3, and p5, the
activins, and the bone morphogenetic proteins (BMPs)184. They are involved in
critical vascular processes such as development^ 186? angiogenesis^^, and
vascular repair and also in cellular proliferation (endoglin can modify
TGFpl inhibition of cellular proliferation via downregulation of c-myc mRNA)1893
stimulation of cell-matrix adhesion *89, haematopoiesis, immune regulation 190,
inhibition of oncogenesis 184, and stimulation ofwound repair^l. TGFpi null mice
behave very similarly to endoglin null mice and ALK1 null mice dying at gestational
age 9.5-11.5 days due to defects in yolk sac vasculogenesis and haematopoiesis185.
Abnormalities in signalling by the TGFP superfamily are thought therefore to
contribute to many different disease processes including importantly oncogenesis,
atherosclerosis, pulmonary hypertension and fibrosis. Signalling is mediated by two
of a series of serine/threonine kinase receptors occurring in two forms, type I and
type II 192, jn a complex. The type I receptors transduce signals to downstream
targets, Smadsl 80 193 194 These receptors however require first to be activated by
a type II receptor which itself has been activated by binding of an appropriate
ligand!95 196 jhe TGFP isoforms and activin type I bind ligands only on
coexpression of type II receptors 195 197 198 jhe ligand specificity of the type I
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receptor is defined by the type II receptor197 por example, for TGFp1 the type II
receptor, TpRII, confers ligand specificity on the type I receptor TpRI. In the BMPs,
the type I receptor can bind ligand independently but still requires a type II receptor
for transduction of the signal 199-201 TGFP isoforms and activins can signal
through the same downstream components, Smad2 and 3202-204 gMPs activate
Smadl, 5, and 8 signalling pathways ^ 94 205-207 yhe possibility that Smad2 has a
tumour suppresser function has been raised as Smad2 lies within a 3 megabase region
ofDPC4 on chromosome 18q21.1, a region often deleted in human cancers204
Endoglin is a trans-membrane glycoprotein 208 ft was identified as a component of
the TGFP receptor system binding TGFpi and p3209 which was prompted by
observations that endoglin had a similar structure and distribution to betaglycan, a
type III receptor210. Betaglycan can bind TGFP 1, 2, and 3211. It presents the
bound TGFp ligand to the type II receptor which is able to bind the ligand with much
greater affinity than it can bind unbound TGFp211, This is especially so for TGFP2
which has a particularly low affinity for the type I and II receptors in the absence of
betaglycan211. Betaglycan is then displaced from the complex by the type I
receptor211. Membrane bound betaglycan thus upregulates cell responsiveness to
TGFP unlike soluble betaglycan which binds TGFP but, as it does not enhance
binding to membrane receptors, acts as a downregulator of TGFp effects212 It had
been suggested that endoglin functions similarly by affecting the binding ofTGFp 1
and P3 to the signalling receptors209 213 214 However recently it has been shown
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that endoglin in fact needs coexpression of a ligand binding receptor in order to
interact with a ligand^O? Furthermore it does not alter overall binding to the kinase
receptors but mimics the specificity of the receptor with which it interacts^?. Since
it cannot bind ligand it is not a true receptor but is better defined as an accessory
protein for the TGFp superfamily207 Endoglin can bind TGFpl and P3 by
interacting with the TpRII receptor and can bind activin-A and BMP-7 by
association with activin type II receptors, regardless ofwhich type I receptor is
expressed207 It also interacts with type I receptors ALK3 and ALK6 which bind
BMP-2^07 Endoglin cannot however interact with BMP-7 bound to BMP type II
receptors indicating specificity of its action^07 since endoglin does not alter overall
binding to kinase receptors and also as it interacts with many different signal
transducing type I receptors, it has been postulated that endoglin could function to
alter receptor activation of downstream signalling events such as Smad signalling or
even could recruit new proteins into the signalling complexes207 This suggests that
it could perform a variety of regulatory roles in diverse cell types according to the
kinase receptors, ligands, and Smad mediators present207
ALK1 is a serine/threonine kinase type I receptor that in vitro can associate with the
TPRII receptor or activin type II receptor, binding TGFpi or activin respectively,
although with low affinity 180-182 198 However ALK1 was defined as an orphan
receptor since this receptor association had not been demonstrated in vivo and its in
vivo ligand was not known^S. ALK1 has now been shown to bind TGFp l in
conjunction with TPRII receptors in human umbilical vein endothelial cells^O
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ALK1 mediated signalling has also been shown to inhibit TGFpi activity mediated
by the type I receptor, ALK5, suggesting that the balance between ALK1 and 5 may
have a crucial role in angiogenesisl^O It has been shown to activate SmadI and
Smad5 pathways' ^0 194 involved with signalling for bone morphogenetic proteins
which are implicated in various aspects of development^ 206
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1.5. LINKAGE ANALYSIS
Primary references for sections 1.5.1-1.5.4 may be found in references^ 15 anc} 216
1.5.1. ALLELES AND COINHERITANCE
Linkage studies are based on analysing the inheritance of alleles. Alleles are
different states of a locus (a discrete area of the genome for which a gene is one
example). If two loci lie very close together on the same chromosome they will be
inherited together from parent to child and so the child will have the same pattern of
alleles as the parent. As the distance between the two loci increases, the chances of
them being inherited together decreases, as there is an increasing chance of
separation due to crossover at meiosis. This produces a non-parental combination
known as a recombinant.
1.5.2. POLYMORPHIC MARKERS
These are published loci of known location in which a number of alleles are present.
The type commonly used in linkage analysis, and used in my work, are loci which
include a varying number of short tandem repeat sequences with repeats of 2 to 5
base pairs. Because they can be amplified by PCR, they allow more rapid analysis
than previously used markers (restriction fragment length polymorphisms). They
also have more than 2 different alleles so are usually more polymorphic. If the
parents have 4 different alleles, i.e. both are heterozygous, then the allelic inheritance
by the offspring is much more informative than otherwise i.e. it is possible to tell
exactly which allele the offspring has inherited from which parent. The
heterozygosity index (H.I.) provides a direct estimation of how many individuals will
be heterozygotes. The polymorphism information content (P.I.C.) estimates the
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probability that an offspring's genotype will allow the deduction of which of the
affected parent's alleles it has received. These values are published with the marker.
It is obviously prudent therefore to choose markers with a high H.I. and P.I.C. in
order to obtain informative results. Since this work was initiated, a new technique
for large-scale association genetics studies has been developed. This uses single
nucleotide polymorphisms (SNPs) which occur once every 100-300 bases throughout
the genome. A database of SNPs is available at The National Center for
Biotechnology Information (NCBI), website http://www.ncbi.nlm.nih.gov/.
1.5.3. GENETIC DISTANCES
In one Morgan of genetic distance there will be, on average, one crossover per
meiosis. Its derivative, the centiMorgan (cM), is approximately equal to a physical
distance of one megabase assuming a sex-averaged genetic map of 3,000 cM and
3xl09 base pairs in the haploid genome. However genetic distances are not exactly
the same as physical distances due to double crossovers and some areas being more
prone to crossovers than others. 1 cM represents a 9 of 0.01. 0 is the recombination
fraction where
q= the number of recombinants
the total number of offspring
Under conditions of free recombination, either because loci are on different
chromosomes or because they are widely spaced on the same chromosome, 0 is 0.5
(the maximum value of 0). As 0 decreases it reflects the appearance of fewer
recombinants than would be expected by chance alone suggesting that the two loci
lie close to each other.
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1.5.4. LOD SCORES
To define the allelic inheritance of polymorphic markers known to lie close to the
locus of interest (in this study the HHT disease-causing gene), mathematical
qualification of the likelihood ofmarker positions is derived from the lod score. In
the case of disease gene analyses, if the same polymorphic marker allele is always
transmitted from affected parent to affected offspring, but not to unaffected
offspring, it indicates that the marker is likely to lie close to the disease-causing gene
in the pedigree as the mutant allele of the gene would be very unlikely to be
separated from the marker allele at meiosis. However if the affected parent's alleles
are randomly inherited it suggests that the marker is not close to the disease-causing
gene. Linkage analyses mathematically quantify the likelihood of two loci being
linked, and therefore in this case a marker gene lying close to a disease-causing gene.
The lod score Z represents:
Lod score (Z) = Logio livelihood of observations if loci linked, distance 6 apart
likelihood of observations if free recombination (0=0.5)
By definition at 0 = 0.5 (free recombination) the lod score is 0. A positive lod score
implies that the observation is more likely to reflect linkage than chance with a score
of+3.6 or more indicating linkage to a new autosomal location at a significance level
of p<0.05. A score of only +1.2 or more is required to significantly (p<0.05) prove
linkage to a known site. The more negative the lod score, the more likely that the
observations are not due to linkage, with a score of -2 or less significantly excluding
linkage at a significance level of p<0.05. Two point lod scores were calculated in
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this work usingMLINK and GENEHUNTER computer programmes via the Human
Genome Mapping Project, website http://www.nhgri.nih.gov/HGP/.
1.5.5. POTENTIAL PITFALLS IN LINKAGE ANALYSIS
Linkage analysis is an extremely powerful tool enabling the identification of the site
of a disease-causing gene in families with inherited disease. The strength of the
analysis can be reduced by either false generation of inappropriate lod scores, or lack
of detection of true linkage. Potential ways in which these problems can result are
outlined below, according to whether these derive from errors in family pedigree
assignment, disease phenotyping or DNA sample numbering, or whether they reflect
inherent limitations of the methodology.
1.5.5.1. MISPHENOTYPING
In the linkage programmes used in the work in this thesis, MLINK and
GENEHUNTER computer programmes via the Human Genome Mapping Project,
website http://www.nhgri.nih.gov/HGP/. affected individuals' results are assumed to
reflect inheritance of the disease gene, and therefore the analyses require the
definition of affected disease status with 100% accuracy. Early studies ofHHT
linkage analyses were sometimes hampered or delayed by difficulties in phenotyping
individuals, particularly by groups who used epistaxis alone as definite indicator of
affected status. Because of this the HHT Foundation International scientific
committee reviewed the then criteria for diagnosis ofHHT34? and established stricter
requirements for a definite diagnosis ofHHT^ 17 Throughout this work disease
status was designated using these stricter international consensus criteria^ 17 (see
Section 2.1.3). Particular care was taken to avoid misinterpretation of epistaxis and
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telangiectasia (see Section 2.1.2.2) with exclusion from further analysis, if necessary,
of any individuals where interpretation was difficult (see Section 2.1.2.2). Exclusion
of the diagnosis ofHHT is more problematic clinically due to age-related penetrance
(though, in practice, of less importance in the linkage analyses as the programme
parameters may be set to allow for a degree of diagnostic uncertainty in clinically
unaffected individuals). At less than 12 years of age, penetrance ofHHT is low (less
than 80%35)5 and there is little data derived from analyses if the penetrance value has
to be set below 75%. For this reason apparently unaffected children under the age of
12 years were excluded from molecular analysis (see Section 2.1.3). The linkage
programme parameters were then used, in this work, to take age-related penetrance
into account in older clinically unaffected individuals, setting penetrance values at
p=0.8 between ages 12 and 35 and p=0.95 for individuals aged over 35, according to
published data on penetrance in HHT30 34 35 (see Section 2.9.2).
1.5.5.2. NON PARENTAGE
Incorrect assigning of parentage as stated by the family, or erroneous sample mixing,
is usually quickly highlighted as non-Mendelian patterns of inheritance ofmarker
alleles result. The program MLINK will not proceed to generate lod scores in the
presence of non-Mendelian inheritance. In theory Mendelian inheritance could occur
in cases of non-parentage if the "false" parent had two alleles ofwhich at least one
and possibly both were the same as in the true parent. As over 50 different
polymorphic markers with allele frequencies of between 0.1-0.3 have been studied in
all of these families in the Shovlin laboratory, always with Mendelian inheritance,
the probability of coincidental allele sharing on each occasion of non-parentage is
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exceedingly remote (in the region of 0.350 for any one family). The only realistic
means in which non-paternity could be an issue is if there was genuine sharing of all
alleles by the "false" and "true" parent being identical twins but, in this case, the
parents would be genetically identical and linkage analysis would not be affected.
Similar considerations apply in the case of offspring, for example adopted children
would have no higher chance of sharing their adoptive parents' alleles than the
general population and the probability that we would miss this with over 50 markers
studied would again be in the region of 0.350 . We therefore did not consider non-
parentage to be an issue in these families studied in this work.
1.5.5.3. INHERENT LIMITATIONS IN LINKAGE STUDIES
The potential of linkage to determine the site of a locus or disease gene critically
depends upon the presence of neighbouring polymorphic markers in which
informative alleles are faithfully passed on to individuals' descendants.
1.5.5.3.1. MARKER DISTRIBUTION
Lack of appropriate polymorphic markers was the major limitation to early linkage
studies which were only able to compare the location of one gene with a known
function to another218 219 jhe principles of creating a map using anonymous
DNA markers throughout the human genome were delineated more recently, but this
was initially again restricted to a relatively limited map of widely spaced
markers220 with the discovery of the short tandem repeat polymorphisms, such as
(CA)n repeats, virtually all areas of the genome became accessible to these studies.
It is therefore now highly unlikely that lack of a suitable marker would be the reason
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why linkage would be missed, even if the locus under study lay in a relative hot spot
for recombination.
These considerations are advanced even further with the discovery and utilisation of
single nucleotide polymorphisms (SNPs), although these were not used in this study.
The human SNP map was published in February 2001221 W1th 1.42 million SNPs,
with a SNP on average every 1,000-2,000 nucleotides222 223
1.5.5.3.2. REDUCED ALLELE INFORMATIVENESS
If insufficiently polymorphic, there is a significant chance that for any given marker
it will be impossible to assess which parent's alleles a particular offspring has
received. This is the essential prerequisite for linkage studies, estimated for each
marker as the polymorphism information content (PIC)220 [f a|] markers in the
vicinity of a particular locus have a low PIC, particularly in the families derived from
common population pools, then the effective distance to the nearest informative
polymorphic marker will be reduced. This results in the possibility that linkage
might be missed.
Informativeness ofmarkers is also reduced in extended families connected by
numerous deceased ancestors, since it is impossible to assess whether the allele
apparently segregating with disease is identical to that segregating elsewhere in the
pedigree, rather than being brought in incidentally by an unaffected spouse. The
latter is more likely to occur if the allele is particularly frequent in the population.
Since disease allele frequencies are generally set at 10% to calculate initial lod
scores, wherever co-inheritance stems through a deceased ancestor the linkage
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programme will assign an artificially high probability of linkage. In this setting lod
scores may be misleadingly high. This risk is reduced if the study focuses on large
sibships which reflect fewer parental pairs.
1.5.5.3.3. GENOME INSTABILITY
Linkage depends on faithful transmission of alleles from parent to child. This will
not occur if the polymorphic alleles undergo a spontaneous mutation during meiosis
resulting in apparent non-parentage or, more rarely but ofmore concern to linkage
analyses, apparent inheritance of a disease-associating allele. In general, the
spontaneous mutation rate of human genomic DNA is approximately 10~9 to 10"12
errors per base per generation224 Short tandem repeat sequences, which were used
in this study as polymorphic markers, arose by replication slippage, and might be
suspected to be prone to a higher mutation rate than other areas of the genome.
However their spontaneous mutation rate was estimated as 0.03% in over 17,000
meioses225 Certain diseases, such as familial non-polyposis colon carcinoma,
generate genome instability causing an increased spontaneous mutation rate, thus
reducing the power of linkage analysis. This has not been seen in the tens of
thousands of parent-child allele transmissions in HHT performed in the Shovlin
group, and was therefore not considered a limitation to linkage analysis in this
disease.
1.5.6. LINKAGE STUDIES VERSUS ASSOCIATION STUDIES
Linkage analysis is an excellent tool for studying diseases determined by the action
of a single gene. However it is less useful in non-Mendelian diseases, arising from
the interaction of a number of genes and environmental influences, as studies of
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small numbers of extended pedigrees containing large numbers of affected
individuals will not yield the same results given that the mode of inheritance is
unknown and a number of genes with segregating alleles in each generation is
involved. One tool for tackling this is the association study. In this, genotypes in
cases and controls at a genetic marker of interest are compared and the difference in
the allele frequencies between cases and controls interpreted as evidence in favour of
association of one or other allele at the marker of interest with disease. Unlike a
linkage study it does not have to be carried out within a family group. Whereas
linkage is a property of loci, separated by the same genetic distances in all
populations, association (also known as linkage disequilibrium) is a property of
alleles 226
The feasibility of analysing more complex genetic traits demands a higher density
map of polymorphisms than the series of short tandem repeats sequences used in
linkage studies in monogenic disease. With a SNP on average every 1,000-2,000
nucleotides224 225^ SNPs are proving particularly useful in association studies
looking at diseases with a complex, multigene basis. In addition each SNP can be
classified as to whether it is likely to be directly functional as many occur in coding
sequences (when the encoded protein may be altered) or regulatory regions of the
genome223
Understanding of the genetic basis of disease, whether the disease is due to a single
gene disorder, multigenic, or a combination ofmultigenic and environmental factors,
through linkage and association studies should lead to enormous therapeutic
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possibilities from gene therapy, through pharmacogenomics, to primary
prevention227
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1.6. INTRODUCTION TO EXPERIMENTALWORK
From our current knowledge of the molecular mechanisms underlying HHT and its
clinical implications, my work has been based on two separate hypotheses. The first
is that mutations in the endoglin promoter region could account for disease in
endoglin-linked families. The second separate hypothesis is that pulmonary
involvement could occur in HHT families unlinked to endoglin and ALK1 but instead
linked to a third gene.
Hypothesis 1: Mutations in the endoglin promoter region could accountfor disease
in endoglin-linkedfamilies
Not all mutations have been found in endoglin-linked families studying all coding
regions and splice sites of the gene^. Given that haploinsufficiency is the
prevailing model in endoglin-linked families^ 148^ jt seems likely that mutations in
the promoter region of the gene could account for disease.
The 8 HHT families identified for this work were chosen as 4 had previously been
shown to be linked to endoglin but no mutations had been found by Southern
blotting, cycle sequencing of all known exons and intron/exon junctions, and cycle
sequencing of the entire cloned DNA^. No mutations had been found in the other 4
families, using the same techniques, but they were too small to allow significant
linkage to an HHT gene to be made^^.
In other work the term "mutation" has been used to describe any permanent variation
between template and daughter sequences in DNA polymerisation. However in this
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work mutation is defined as this variation occurring in an allele that is only present
cosegregating with a particular disease trait and for which there is independent
evidence that this variation is the cause of the disease. In this work a variation in an
allele which is incidental to the gene product and not a disease causing mutation is
described as a polymorphism.
Hypothesis 2: HHTfamilies with pulmonary involvement may be unlinked to the
PA VMgene, endoglin, andmay be unlinked to both known HHT genes, endoglin and
ALK1
The work ofPiantanida^O suggests that a third gene for HHT could exist. While no
pulmonary involvement was seen in this pedigree, PAVMs have been shown not to
occur exclusively in endoglin-\ivke<\ families^ 37 The hypothesis, therefore, seems
plausible.
The HHT families chosen for this study were identified as being suitable as they had
pulmonary involvement and initial analysis in 1992 suggested that they were
unlinked to endoglin}Linkage analysis was undertaken using the principles as
discussed in Section 1.5.
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FIGURE 1.1 HISTOLOGY OF MICROSCOPIC PAVMS
Haemotoxylin and eosin stained slide, viewed by light microscopy, showing
microscopic PAVMs.
I would like to thank Dr D. Lamb and Professor W. MacNee for this figure.
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FIGURE 1.2 TELANGIECTASIA OF THE LIPS
Telangiectasia of the lips.
I would like to thank Dr C.L. Shovlin for this figure.
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FIGURE 1.3 CT HEAD SCAN SHOWING CAVM
CT head scan showing CAVM marked by the arrow.
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FIGURE 1.4 CHEST X-RAY SHOWING PAVM
PAVM on chest X-ray indicated by the arrow.
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FIGURE 1.5 CHEST CT SCAN SHOWING PAVM
CT scan of chest showing PAVM indicated by the arrow.
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FIGURE 1.6 PULMONARY ANGIOGRAM PRE AND POST
EMBOLISATION
Pulmonary angiography showing PAVM before treatment in A) and after coil
embolisation in B) (marked with arrows). I would like to thank Dr K.
McBride for performing the investigation.
2. MATERIALS AND METHODS
Both clinical and molecular techniques were used.
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2.1. CLINICAL
2.1.1. ACQUISITION OF SUBJECTS
Current studies were performed with the approval of the Multicentre Research Ethics
Committee of Scotland (MREC). Families affected by HHT were initially identified
in 1992^5 37 when one individual from each presented to the Hammersmith Hospital
for management ofPAVMs. Families of the individuals were clinically evaluated at
that time by Dr Claire Shovlin (CLS), my supervisor, in the same way as
documented below.
2.1.1.1. LINKAGE ANALYSES
Two of the families (families S & P) were further assessed by myself and CLS six
years later. These families were identified as being suitable for further linkage
analyses as analysis in 1992 indicated that they were not linked to endoglin. Original
members were reviewed and additional members were assessed. After linkage
results were obtained for these two families, two additional families (families V and
T) with PAVMs were studied. They had been reported as being unlinked to
endoglin35 37 They had been assessed clinically in 1992 by CLS and were not
assessed further clinically by myself.
2.1.1.2. PROMOTER ANALYSES
Eight of the families identified in 1992 were studied further. They were chosen for
this work as four had previously been shown to be linked to endoglin but no
mutations had been found. No mutations had been found in the other four families
but they were too small to allow significant linkage to an HHT gene to be made^.
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These families had been clinically evaluated by CLS in the same way as documented
below. They were not assessed further clinically by myself.
2.1.2. CLINICAL EVALUATION
With written consent individuals were evaluated clinically in their own homes with a
full medical history. This included questions regarding epistaxis, gastrointestinal
bleeding, anaemia, dyspnoea and haemoptysis, and symptoms suggestive of transient
ischaemic attacks (TIAs) (see Appendix AT Physical examination for telangiectasia
on the lips, face, hands, and on the buccal and nasal mucosae was performed. The
presence of central cyanosis and finger clubbing, which could be due to PAVMs, was
noted. Full blood counts (FBCs) were performed when appropriate (to assess for
anaemia or polycythaemia). If necessary, further information was obtained from GPs
and local physicians, with patient consent.
2.1.2.1. SCREENING FOR PAVMS
Screening for PAVMs is recommended for all individuals with FIHT^3 jn view of the
risks of paradoxical embolism ifPAVMs are left untreated and the safe therapeutic
methods which exist to limit these complications. As respiratory physicians, in this
study, we wanted to perform an assessment in addition to clinical history and
examination, in order to direct potentially affected patients to local respiratory
services for formal evaluation.
Although physiological considerations suggest that oxygen saturations (Sa02)
detected by pulse oximetry might be too imprecise to use to predict for the presence
ofPAVMs113, this method has been previously validated in PAVM patients11^.
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Thompson et afi 14 use(j Biomeda pulse oximeters and a protocol ofmeasurements
for 10 minutes in both the supine and erect postures. In their hands, erect Sa02 <
96% had a sensitivity of 73% and specificity of 35%, and this value was
recommended for a screening cut-off. In addition, in their population, supine-erect
Sa02 was significantly greater in the PAVM rather than non-PAVM group: 1.7 (SD
2.7%) vs 0.3 (SD 1.5%), p=0.01.
We elected to base a simple screen on these results. We purchased an Ohmeda 3800
oximeter and used the Thompson protocol ofmeasurements for 10 minutes in both
the supine and erect postures. Diagnostic cut-offs for results sufficiently suggestive
ofPAVMs to advise (with patient consent) referral to local respiratory physicians
were established. These were suspicious symptoms (e.g. unexplained haemoptysis)
or signs (e.g. clubbing, central cyanosis), Sa02 erect of< 96% (as recommended by
114), or Sa02 supine-erect greater than 2SDs beyond the mean in the non-PAVM
group in H4, i.e. 0.3% +[2x 1.5%] = 3.3%.
2.1.2.2. ACCURATE PHENOTYPING
Accurate phenotyping is critical. Care was required particularly in evaluating certain
manifestations ofHHT. It is important that epistaxis is spontaneous and not
precipitated by trauma. Two individuals gave a history of nose bleeds which had
only occurred after possibly being hit on the nose. They could therefore not be given
a definite phenotype and were given the disease status "unknown" (see Section
2.1.3). Telangiectasia may also be misdiagnosed. All telangiectasia were assessed
by myself and CLS rather than individual reports of them being accepted.
Differentiation from spider telangiectasia can be difficult, although they are
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morphologically distinct.228 One individual, with a history of heavy alcohol usage,
had to be designated "unknown" (see Section 2.1.3) as her telangiectasia occurred in
the presence of such extensive spider telangiectasia that we were not confident to
diagnose a subset ofHHT telangiectasia with certainty.
2.1.3. DESIGNATION OF DISEASE STATUS
Disease status was designated using the current international consensus criteria229
Affected status was assigned in the presence of any three criteria: affected first
degree relative; recurrent, spontaneous epistaxis; telangiectasia; documented visceral
manifestations. Ifonly two of the four criteria were present (affected first degree
relative and epistaxis or telangiectasia), unknown status was assigned and the
individual excluded from molecular analyses. However if the offspring of the
individual was affected, a diagnosis of obligate affected was made. Apparently
unaffected children under the age of twelve years were designated unknown, as
penetrance is less than 80% at this age^4 35
2.1.4. SAMPLE COLLECTION
With consent each individual had 20mls ofblood venesected into a heparinised 50ml
Falcon tube. This was for later DNA extraction and, in some cases, leukocyte and
plasma preparation. Where appropriate 2.7mls of blood was also placed in an EDTA
tube for a full blood count (FBC) to be performed. The samples were collected on
trips which lasted several days so were kept at ambient temperatures for about three
days. The samples in the Falcon tubes were then placed at -70°C while awaiting
DNA extraction. FBC samples were sent to the haematology laboratory at the Royal
Infirmary of Edinburgh for analysis.
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2.2. DNA EXTRACTION
Standard proteinase K digestion and phenol-chloroform extraction methods were
adopted^^O w(th ethanol precipitation and resuspension in Tris-buffered EDTA:
2.2.1. GENOMIC DNA
Genomic DNA was extracted from all the whole blood samples obtained from
families S and P, which had been previously placed at -70°C. Half of the total
original sample for all family S members had already been used for leukocyte and
plasma extraction. Half of the total remaining sample (half of the total original
sample for family P members) was prepared so that more of each sample was
available in case of problems. Frozen samples in heparinised Falcon tubes were
thawed in a water bath at 37°C. They were diluted in an equal volume of autoclaved
phosphate buffered saline (PBS) and centrifuged at room temperature at 3500g for 15
minutes. To commence deproteinisation the resulting cellular pellet was resuspended
in extraction buffer (see Appendix B) (the volume of this used was three quarters of
the original sample volume), and incubated at 37°C for one hour. The buffer
contained the ionic detergent 10% sodium dodecyl sulfate (SDS) (Gibco) and EDTA
(Sigma) which inhibits DNA endonucleases (DNAses). RNaseA (Sigma) was added
to the buffer at 20pg/ml to remove RNA. After this incubation, deproteinisation was
completed with proteinase K (Sigma). Initially it was added to each sample to give a
concentration of 20mg/ml and incubated at 50°C for 3 hours swirling regularly.
However, despite this being a higher concentration than suggested by Sambrook2305
it was always insufficient, with several more additions of proteinase K usually being
required. The samples were incubated after each addition either at 50°C for 3 hours
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or 37°C overnight. Double the original volume of proteinase K was therefore added
each time which decreased the number of additions required.
RNaseA and other lipid soluble cellular debris was removed by extraction with
phenol and/or chloroform. For each extraction an equal volume of the appropriate
phenol/chloroform solution was added and mixed by inversion by hand for 10
minutes. This minimised shearing forces on the DNA. The sample was then spun at
2000 rpm at room temperature for 15 minutes and the resultant supernatant removed
using cell saver pipette tips, again to decrease shearing forces. The next extraction
was then commenced on the supernatant. Two phenol extractions (equilibrated
phenol (Sigma)), followed by a phenohchloroform 50:50 extraction
(phenol:chloroform isoamylalcohol 25:24:1 (Sigma)), and finally a chloroform
extraction (chloroform isoamylalcohol (Sigma)) were performed.
To precipitate the DNA, O.lx volume (of the final total volume) of 3M sodium
acetate and 2.5x volume (of the volume of supernatant remaining from the final
chloroform extraction) of 100% ethanol was added to the supernatant. The DNA
precipitated at room temperature and could be lifted out with a sterile glass rod. The
precipitated DNA was washed twice in 70% ethanol to remove salts and small
organic molecules and air dried. Vacuum drying in a Savant speedvac was tried but
tended to make resuspension more difficult. The DNA was resuspended in
approximately 500pl of GTE.
The DNA concentration, integrity, purity, and resuspension were assessed by agarose
gel electrophoresis of 1 pi of extracted DNA in comparison to 1pi ofAHindlll
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marker. If residual contaminating DNA and protein had been excessive, relevant
purification steps could be repeated, although this did not occur. If resuspension was
problematic aliquots of the DNA were diluted further with genomic TE, heated to
37°C and vortexed (gently to minimise shearing of the DNA), prior to use for PCR.
2.2.2. PLASMID DNA
Plasmid DNA clones were grown to saturation in 7mls LB (supplemented with 25-50
jug/ml ampicillin for ampicillin selection). After centrifuging at 2500 rpm, at room
temperature for 5 minutes, the resulting cellular pellet was resuspended in 150jul
Genomic tris EDTA (GTE) (see Appendix B). Bacterial lysis was performed by
alkaline lysis^^O by adding 300pl of 1% SDS (to denature all DNA). The reaction
was vortexed vigorously and iced. Subsequent addition of 300pl of ice cold 5 molar
(M) potassium acetate pH 5.0 followed by vortexing, icing for 5 minutes, and
vortexing again, allowed the covalently-closed plasmid DNA to reanneal rapidly,
while most of the chromosomal DNA proteins and DNA precipitated with the newly
complexed SDS and potassium and was removed by centrifuging for 10 minutes at
4°C. lpl of lOmg/ml RNaseA, to remove residual RNA, was added to the
supernatant and incubated at 37°C for 30 minutes prior to proceeding to one
phenol:chloroform 50:50 extraction using the same technique as for genomic DNA
(See Section 2.2.1).
Precipitation of the DNA was performed using the same technique as for genomic
DNA i.e. ethanol precipitation (See Section 2.2.1). Since plasmid DNA is composed
of shorter fragments ofDNA than genomic DNA precipitation occurs less readily. It
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was enhanced by the addition of IjliI of glycogen to coprecipitate as a carrier
molecule and the sample placed at -70°C for 20 minutes followed by centrifugation
at 4°C for 20 minutes. The precipitated DNA was washed and dried in the same way
as for genomic DNA and resuspended in 50pl of GTE.
The insert DNA was released from plasmid DNA (pGEM-T vector, Promega) by
digestion with EcoRI using standard protocols (see Section 2.5.1). The digest was
then assessed by agarose gel electrophoresis.
2.2.3. DNA EXTRACTION FROM AN AGAROSE GEL
This was performed using the Wizard PCR Preps DNA Purification System
(Promega). PCR products were separated by TAE low melting point agarose gel
electrophoresis (see Section 2.4.1.1). The DNA band was cut from the gel using a
sterile blade aiming to obtain no more than 300pl of agarose. Exposure of the DNA
to UV light was minimised by excising it quickly under a transilluminator UVP with
the power in the "lo" position. The sample was melted in a 1.5ml eppendorfer tube
by incubation at 70°C. 1ml ofWizard Preps resin was mixed with the melted
agarose by pipetting for 20 seconds. Vortexing was avoided to minimise shearing
forces on the DNA. The mix was drawn into a WizardMinicolumn using a syringe.
The minicolumn was washed with 1ml of 80% isopropanol and centrifuged at
12000g for 20 seconds to remove residual isopropanol. The DNA was eluted from
the minicolumn by applying 50pl of double distilled water (at room temperature if
the DNA fragment was less than 3kilobases (kb), at 65°C if the fragment was 3kb or
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more), waiting for 1 minute, and centrifuging at 12000g for 20 seconds. The DNA
was stored at 4°C.
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2.3. PREPARATION OF LEUCOCYTES AND PLASMA
Half of the total volume ofwhole blood samples from all family S members was
used to extract plasma and leukocytes using a Ficoll preparation. Samples were
thawed in a water bath at room temperature and diluted with an equal volume of
autoclaved phosphate buffered saline (PBS). The same volume as the original blood
sample of histopaque 1077 (Ficoll) was overlaid in a 50ml Falcon tube with the
diluted blood very slowly to prevent mixing of the two layers. This was centrifuged
at 2200 rpm, for 20 minutes at room temperature, with no brake so as not to disrupt
the cells. This separated the sample into 4 layers: plasma, leukocytes, histopaque
1077, and erythrocytes from top to bottom respectively. The plasma was removed
and stored at -70°C. The leukocytes were removed and washed twice with 50mls
PBS, with centrifugation at 1600 rpm for 15 minutes then 1200 rpm for 7 minutes
between washes (both times at room temperature with no brake). Leukocytes from
this preparation were stored by resuspending the pellets with 1ml RPMI-1640
medium (Sigma) containing previously added foetal calf serum, 10,000 units of a
penicillin/streptomycin mix, and L-glutamine (5mls of 200mM stock), and placing
on ice. 1ml of foetal calf serum containing dimethylsulphoxide (DMSO) (Sigma),
previously iced, was mixed with this and the resulting mixture placed in a cryo tube,





A range of agarose concentrations (0.8-4%) were used according to the DNA
fragment size to be studied^^O Low melting temperature products, seaplaque
agarose (FMC Bioproducts), were used either if a sample was being gel purified or to
enable a 4% gel to be used, as 3% seaplaque agarose, 1% normal agarose (seakem
LE agarose (FMC Bioproducts)). Gels were prepared and run in lx tris borate
EDTA (TBE) (Gibco) (see Appendix B) or lx tris acetate EDTA (TAE) (Gibco)
buffers. TAE was always used if gel purification was being performed. 0.5pg/ml
ethidium bromide was added to the gel to allow visualisation of the DNA. A loading
buffer containing glycerol and bromophenol blue (see Appendix B) was used.
Commercially supplied markers ((|)xl74HaeIII digest or AHindlll digest) were used.
Negative controls were loaded for each reaction.
2.4.1.2. DENATURING POLYACRYLAMIDE
These gels were used to allow size separation of sequencing products, or radioactive
PCR products in linkage analysis. Samples were denatured by the addition, for
sequencing products, of 5pi of stop solution from the Stratagene Cyclist Taq DNA
sequencing kit or lOpl of denaturing gel loading buffer (see Appendix B) for PCR
products. Each sample was heated to 95°C for 7 minutes then snap cooled to 0°C.
Samples were thereafter kept on ice until loading. 6% gels, used for PCR product
separation and some of the sequencing, were made with 42g of urea, 12mls of
lOx TBE, 20mls of acrylamide-bisacrylamide 30% (w/v) (37.5:1 solution) and made
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up to a final volume of lOOmls with double distilled water. For 5% gels, used to
resolve larger sequencing products, lOmls of 50% longranger solution (Sigma) was
used instead of the acrylamide-bisacrylamide 30%, with more water required, again
giving a total volume of lOOmls. All gels were polymerised with 50pl N,N,N',N'-
tetramethylethylenediamine (TEMED) and 500pJ of freshly made 10% ammonium
persulphate. Gel plates were prepared by washing thoroughly with decon neutrocon
detergent followed by 100% ethanol, and covering with a silicon containing solution,
sigmacote (Sigma) to allow easy pouring and removal of the plates from the gel.
Gels were run in 0.6x TBE at 60W for one and a half to three and a half hours
according to the size of the product being run. After transfer to Whatmann 3MM
paper they were dried at 80°C on a vacuum slab dryer (BioRad).
2.4.2. DETECTION SYSTEMS
Agarose gels were visualised by ultraviolet illumination with a UVP transilluminator
and detection with Grab-IT computer software. Polyacrylamide gels were exposed
to Biomax Kodak film, using an intensifier screen, at -70°C . The film was
developed in an X-ograph imaging systems processor. Areas of interest on some of
the linkage gels, detected by Kodak film, were then analysed using a Molecular
Dynamics phosphorimager to obtain intense banding rapidly.
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2.5. ENZYME MANIPULATIONS OF NUCLEIC ACIDS
2.5.1. RESTRICTION ENDONUCLEASE DIGESTS
PCR and cloned products were purified by ethanol precipitation (see Section 2.2) and
resuspension in double distilled water to remove buffers and other reagents which
could interfere with the restriction enzyme activity. To maximise enzyme activity
DNA was digested in a 20-50pl volume with a tenth volume of the appropriate
lOx buffer, and less than a tenth enzyme volume (to prevent glycerol inhibition of
the reaction) using a 2-10 fold excess of enzyme over DNA. Acetylated bovine
serum albumin (BSA) was added to a final concentration of 0. lmg/ml, as
recommended by the manufacturer, to improve the efficiency of digests of impure
DNA. The digests were incubated for 1-4 hours at the optimum temperature as
specified by each enzyme (for the majority 37°C, for BsrI 65°C). For double digests
enzymes with compatible buffers were selected.
2.5.2. LIGATIONS
Tth/vent polymerase based PCR products have blunt ends. These were changed to
cohesive ends, to improve the efficiency of the subsequent ligation, by the addition
of an adenine nucleotide. This was achieved by incubating a particular PCR product
in a Taq based 50pi reaction at 75°C for 2 hours, containing a fifth volume 5MM
dATP. The ethanol precipitated product was then ligated using DNA ligase from the
pGEM-T vector Promega kit to form phosphodiester bonds between adjacent
3'hydroxyl and 5'phosphate groups of cohesive ends. A lOpl reaction containing
lpl of lOx ligase buffer, lpl of pGEM-T vector, 1-3 units ofDNA ligase, and the
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DNA to be ligated was incubated at 15°C overnight to optimise annealing versus
enzyme activity.
2.5.3. LABELLING OF PCR PRODUCTS
PCR products were labelled using Redivue P y-ATP (Amersham) for linkage
analyses and thermal cycle sequencing. For linkage analyses only one primer and
therefore one PCR product strand was labelled, instead of both, as this is generally
known to achieve better resolution of the two alleles. 4pg of the 5'primer was
endlabelled at 37°C for 1 hour in a 25pi reaction containing tenth volume of
•5-3
lOx polynucleotide kinase buffer, 6pl ofRedivue P y-ATP, and 10 units ofT4
polynucleotide kinase. A similar reaction was used to label the primer for thermal
cycle sequencing except only lOOng of primer was labelled to improve specific
activity.
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2.6. DNA AMPLIFICATION: POLYMERASE CHAIN REACTION
Reactions were mainly performed in thin walled microtubes (Advanced
Biotechnologies) where efficient heat conduction through the tubes allowed the use
of short cycle times. They were amplified in a PTC-200 thermal cycler (MJ
Research) which has a heated lid preventing evaporation, so no mineral oil was
required. In the first few months ofmy work 500pi eppendorfer tubes were used
instead, with amplification in an early Perkin-Elmer machine. Mineral oil and longer
cycle times were required. Either enzyme derived from the thermophilic bacteria
Thermus aquaticus (Taq) or two enzymes also from thermophilic bacteria Thermus
thermophilus (Tth) and Thermococcus litoralis (vent) were used in reactions and are
discussed below. The optimum concentration of template DNA was assessed by
performing identical PCRs at different template DNA concentrations.
2.6.1. TAQ POLYMERASE-BASED PCR
25pl reaction volumes were used for non radioactive PCRs where short length
fragments (up to 1.5 kb) were to be amplified. The reaction contained template DNA
of optimum concentration as previously assessed (see Section 2.6), a tenth volume of
lOx Taq buffer (containing 50mM Tris-HCl (pH 8.0 at 25°C), lOOmM sodium
chloride, 0.1 mM EDTA, ImM MDTT, 50% glycerol, and 1% Triton X-100),
0.2mM of dNTPs, 0.25pg of 5' and 3' PCR primers and 1.25 units ofTaq
polymerase. Amplification generally used 35 cycles of 95°C for 30 seconds,
published or calculated primer-specific annealing temperature (see Section 2.6.3) for
45 seconds, and 72°C for 1-2 minutes according to product length. To decrease the
possibility of primers misannealing, manual "hot starts" were used in many cases by
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adding the enzyme in a buffered 5ju.l volume at the first annealing step without
stopping the PCR programme. Hot starts were not continued at temperatures higher
than the extension temperature of 72°C for any particular cycle to prevent
evaporation.
lOpl reaction volumes were used for radioactive PCRs in linkage analysis. PCR
product sizes no larger than 280 base pairs were studied. A tenth volume of lOx Taq
buffer (as above) was used with 0.5 units of Taq, 0.2mM of dNTPs, and 40ng of
labelled 5' and unlabelled 3' PCR primers. Amplification used similar steps to those
used in 25pi reactions but only 30 cycles were performed with the final extension
step prolonged by 5 minutes before ramping to 0°C . Hot starts were not used as
they were not required and would have increased the risk of radioactive
contamination.
2.6.2. TTH/VENT POLYMERASE-BASED PCR
Unlike the tris-based Taq polymerase buffer where its acidity increases with
increasing temperatures leading to breaks in the DNA being amplified, Tth/vent
polymerase buffer, which is tricine based, remains neutral. This, coupled with the
"proof reading" activity of vent, allows PCR amplification of much longer fragments
to be achieved. PCR products of 2.7 kb were easily obtained in this work from
cloned and genomic template DNA. Tth/vent based reactions were therefore used in
most of the promoter analysis in order to amplify long sections. 25pi reactions were
used with all reactions employing a manual hot start with 0.6 units of rTth DNA
polymerase XL (Perkin Elmer) in a buffered 5pi volume. The same technique was
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used as for Taq hot starts. 0.33 of final volume of x3.3 Tth XL buffer II (containing
tricine, potassium acetate, glycerol, and DMSO) was used along with 0. ImM of
dNTPs, lpM ofmagnesium acetate, and 0.125jj.g of 5' and 3' primers. Similar
amplification programmes to those for Taq based reactions were used with longer
extension times used (up to three and a half minutes) reflecting the longer fragments
to be amplified.
2.6.3. PRIMERS
Primers for PCRs used in the endoglin promoter analysis were designed using the
promoter sequence (GeneBank accession number AF035753) (see Appendix C).
Oligonucleotides were between 21 and 24 base pairs in length with no more than
60% of the bases being guanine or cytosine. Since these bases have 3 hydrogen
bonds compared to the 2 hydrogen bonds of adenine and thymine, PCR is less
efficient as their percentage increases. This is because the melting temperature, and
thus the annealing temperature, of a primer is dependent on the number of hydrogen
bonds that it contains; the more hydrogen bonds the higher the melting temperature.
It was ensured that there were no complementary sequences within the primer and
that primer ends were not complementary either to each other or to those of the other
primer in the primer pair. The melting temperature for the primer was calculated as
4x(G+C)+2x(T+A)°C . Primers in a pair were designed to have similar melting
temperatures. The annealing temperature used in a PCR programme was calculated
as 5°C less than the lower of the two primer melting temperatures. The calculated
annealing temperature for a primer was not used if it was higher than the extension
temperature. A lower one was used, but did not seem to lead to misannealing as
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frequently as when shorter primers are used at inappropriately low annealing
temperatures. Finally the designed primer was checked by the BLAST programme
from The National Center for Biotechnology Information (NCBI), website
http://www.ncbi.nlm.nih.gov/, to ensure that no similar sequences existed in the
human genome to which it could misanneal.
Primers for PCR used in the linkage work had all been previously published^! 232
(Appendices D and E).
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2.7. DNA AMPLIFICATION: CLONING
2.7.1. INSERT PREPARATION AND LIGATION
PCR products were cloned. Products from Tth/vent polymerase based reactions were
changed from having blunt ends to cohesive ends (see Section 2.5.2). The products
were then ethanol precipitated and the concentration of product assessed by running
a tenth on an agarose gel against a known marker. This allowed optimal insert:
vector molar ratios (1:1 and 3:1) to be calculated for 50ng of a commercial vector,
pGEM-T Vector (Promega). Vector and insert were then ligated (see Section 2.5.2).
A control reaction containing no insert was also performed and used as a control in
transformation.
2.7.2. TRANSFORMATION
Plasmid and insert DNA (2jul of lOjul ligation reaction) were added to 50jul of high
efficiency competent cells (JM 109 High Efficiency Competent Cells (Promega)),
handling the very fragile cells carefully, and placed on ice for 20 minutes. To allow
DNA insertion into the cells, they were heat shocked at 42°C for 45-50 seconds and
then iced for at least 2 minutes. 950pl of room temperature SOC medium was added
and the cells allowed to grow at 37°C for one and a half hours. The transformation
mixture was plated onto previously prepared LB agar plates at a variety of
concentrations and cultured at 37°C overnight. The plates were spread with
ampicillin, using 1,25mg/plate, to select for cells with plasmids which contained an
ampicillin resistance gene. To identify colonies containing the inserts they were also
spread with Xgal (0.75mg/plate) and 1M Isopropylthio-(3-D-galactoside (IPTG) for
blue-white selection. White colonies generally contained inserts. Inserts could also
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be present in blue colonies, however, as in-frame inserts allow read-through and P-
galactosidase activity. Identification of colonies containing the insert was also
performed in some cases by colony PCR. lOp.1 Tth/vent polymerase based reactions
(see Section 2.6.2) were performed using part of a colony (picked up by cocktail
sticks) as template DNA and primers to amplify the insert in question. Colonies of




This was performed by thermal cycle sequencing for products amplified both by
PCR and cloning. The Stratagene Cyclist Taq DNA sequencing kit was used. A
30pl premix was prepared from double distilled water, 4pi of lOx buffer, 16ng of an
oligonucleotide primer end-labelled with Redivue33P y-ATP (see Section 2.5.3), 5
units ofTaq polymerase, and template DNA. Template DNA included 2.5pi of non-
purified PCR product and 3pl of ethanol precipitated digested cloned product. 6.7pl
of premix was dispensed to each of four termination tubes containing 3pi of the
respective termination mixes (ddGTP, ddATP, DDT, dicta). Reactions were
prepared on ice and transferred to the thermal cycler (PTC 100 MJ Research) when
the block temperature exceeded the annealing temperature. Sequencing programmes
used were typically 35 cycles of 95°C for 20 seconds, the calculated annealing
temperature of the specific primer (see Section 2.6.3) for 20 seconds, 72°C for 20
seconds. Samples were then stored at -20°C or immediately size-separated by
polyacrylamide gel electrophoresis after denaturing (see Section 2.4.1.2). After
detection by autoradiography the sequences were read by eye.
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2.9. LINKAGE
2.9.1. ASCERTAINMENT OF PHENOTYPE AND GENOTYPE
Disease status was assigned using the current international consensus criteria229(see
Section 2.1.3). Individuals who were designated status "unknown" were excluded
from linkage analysis. Apparently unaffected children under the age of 12 were
excluded as penetrance is less than 80% at this age^5. Linkage studies were
performed by analysis of short tandem repeat polymorphic markers. Markers of high
heterozygosity were chosen on the basis of their position relative to the genes of
interest and experience in molecular papers (Endoglin35 136- ALK1 137 139)
Primers used to amplify the markers had been previously published^ 1 232
(Appendices D and E). The markers were amplified from the extracted genomic
DNA from each individual using 40ng of labelled Redivue 33P y-ATP 5'primer and
40ng of unlabelled 3'primer in a 1 Ojul Taq polymerase based PCR reaction (see
Section 2.6.1). The PCR products were denatured, size separated by denaturing
polyacrylamide gel electrophoresis, detected initially by autoradiography, and, in
some cases, further by phosphorimager. Allele patterns were assessed by eye by
myself and a second observer (CLS), both of us being blinded to disease status.
2.9.2. LINKAGE ANALYSES
I performed two-point linkage analyses using the programmeMLINK^IS vja Human
Genome Mapping Project (HGMP) computational resources. Based on previously
published estimates^ and previous studies of the families studied this time^
penetrance was set at P=0.8 between ages 12 and 35 and P=0.95 for individuals aged
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over 35 giving two liability classes. A disease gene frequency of 0.0001 was used,
given that the prevalence ofHHT in the population investigated is approximately 1 in
10,000 (see Section 1.1.2), and recombination rates in both sexes were assumed to be
equal. Two point lod scores were calculated initially with equal allele frequencies
and subsequently according to the allele frequencies in the population.
2.9.2.1. MULTIPOINT ANALYSES
The entered data for family S was subsequently compiled into two files (one
including data from markers D9S60, D9S315, and D9S61, the other including data
from markers D12S85, D12S347, D12S368, and D12S325) for multipoint analyses
using GENEHUNTER215, again via HGMP computational resources.
2.9.2.2. HAPLOTYPE ANALYSES
Haplotype analysis of chromosome 9 in Family P was performed by initially
converting the text data files for D9S60, D9S315, D9S61 and HXB to a format
suitable for haplotype analyses using Mega2 via HGMP computational facilities222.
Simwalk2 via the HGMP computational facility22^ was then used to assess the
number of possible haplotype solutions.
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3. ENDOGLINPROMOTER
Hypothesis : Mutations in the endoglin promoter region could accountfor disease in
endoglin-linkedfamilies
Not all mutations have been found in endoglin-linked families studying all coding
regions and splice sites of the gene^. Given that haploinsufficiency is the
prevailing model in endoglin-linked families^? 148^ jt seems likely that mutations in
the promoter region of the gene could account for disease.
The 8 HHT families identified for this work were chosen as 4 had previously been
shown to be linked to endoglin but no mutations had been found by Southern
blotting, cycle sequencing of all known exons (starting 35 base pairs upstream of the
transcription start site using endolF) and intron/exon junctions, and cycle sequencing
of entire cloned DNA^7 (starting 85 base pairs downstream of the transcription start
site). No mutations had been found in the other 4 families using the same techniques
but they were too small to allow significant linkage to an HHT gene to be made^?.
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3.1. AMPLIFICATION OF SEQUENCE
A 3.2 kb sequence, encompassing the endoglin promoter and 605 base pairs spanning
endoglin exon 1 and the start of the first intron, was kindly sent by a collaborator,
Carmelo Bernabeu. At the time it had not as yet been published (it was published 10
months later'33) Primers were designed to amplify the entire 3.2 kb sequence using
Tth/vent based reactions (see Figure 3.1) (see Section 2.6.2 and 2.6.3)(see Appendix
C). Several different primer pairings were tried using DNA clones from a PI library
of human genomic DNA^as the target DNA. The DNA clone spanned the entire
endoglin gene. Primer pairing GW1 (starting 10 base pairs downstream of the 5' end
of the sequence and replicating the sense strand (sense primer)) and GW7 (2.7
kilobases downstream in exon 1 and replicating the antisense strand (antisense
primer)) had reasonable success. A large amount ofPCR product using this primer
pair was obtained when the target DNA was cloned DNA. Restriction endonuclease
digest of the PCR product using Aval and PvuII confirmed that the correct region
had been amplified (see Figure 3.3). Previously prepared DNA from one affected
individual from each of the 6 smaller families and from 2 affected individuals from
both of the 2 larger families (both of which were linked to endoglin) was then used
as target DNA. PCR product was obtained with difficulty with primer pairing GW1
and 7 (see Figure 3.2) and it was not reliable enough to be used exclusively. Smaller
regions of the sequence were therefore amplified using different primer pairings.
Good PCR product, 1.7 kb in length, was obtained with primer pair GW1 and GW3
(see Figure 3.4) using genomic target DNA. Amplification of the sequence starting
immediately 3' to the region amplified by GW1 and 3 and extending to the start of
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exon 1 was far more difficult. This was particularly frustrating as the main
regulatory element was suspected (in fact correctly so^3) to be in this region of the
sequence since it lay immediately upstream of the previously published exon 1
sequence. The difficulty with amplification and the importance of the region were
probably not coincidental. Sequences for transcription factor binding sites and
response elements in this region will occur in many other parts of the genome
making specific amplification of this region alone problematic. Several different
primer pairings were tried including nested primers on PCR products. Using sense
primer GW11, starting 469 base pairs upstream of the transcription start site, with
primer GW7, the region —^469/-+-154 (with respect to the major transcription start site)
was amplified. This was only achieved when 3 pi ofPCR product obtained with
primers GW11 and 7 was used as the target DNA for a further PCR using GW11 and
7 involving a total of 60 PCR cycles. This was not ideal because as the number of
PCR cycles increases, the likelihood decreases of any polymorphism found being
genuine rather than due to a replication error during PCR amplification.
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3.2. SEQUENCING
An attempt to clone the PCR product spanning the entire 2.7 kilobase region between
primers GW1 and 7 was made as this would allow cloned sequencing to be
performed on a single product. However cloning this large fragment was not
successful. Instead DNA from all individuals stated above which had been amplified
with GW1 and 7, or GW1 and 3 and GW11 and 7, was cycle sequenced. Sequencing
throughout the region of these PCR products was commenced (see Figure 3.1).
Using a 5% longranger gel GW3 was used to sequence 273 base pairs at the 3' end of
gel purified GW1 and 3 PCR product. No polymorphisms were found. GW4,
starting 25 base pairs upstream ofGW3 but acting as a sense primer unlike GW3,
was used to sequence 390 base pairs from GW1 and 7 PCR product again using a
longranger gel. This in fact encompassed the region -927/-666 later described as an
Alu sequence Again no polymorphisms were seen. GW8, designed to be a
nested primer to GW7 as it started 23 base pairs upstream ofGW7 and acted in the
same direction, was used to sequence the 3' end of the GW1 and 7 product. GW8
however misannealed to another region of the product producing interesting results
(see Section 3.3). Further sequencing was then focussed to the region immediately
upstream of the major transcription start site. PCR product, from DNA from all
individuals as described above, using primers GW11 and 7 was analysed. This was
the region —469/+154I33 p was fuUy sequenced in both directions using GW11 and
GW9 (204 base pairs downstream ofGW11) as sense primers and GW7, GW15 (63
base pairs upstream ofGW7), and GW12 (263 base pairs upstream of GW7) as
antisense primers. No polymorphisms were found in any individual with any primer.
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Different groups have included different proportions of the untranslated sequence 5'
to the ATG start codon in their mutational screens. More extensive sequence was
spanned in mutational studies by Shovlin et al^7 jn which primer endolF was
derived from sequence 5' to the major transcriptional start sequence. This is 385
base pairs upstream of the ATG start codon as described by McAllister et al^6 and
Yamaguchi et al^7 (who studied coding sequence only) (See Figure 3.5). Thus,
although the region between the 5' untranslated region of exon 1 as described by
Shovlin et aP?, based on the GenBank sequence X72012, and coding sequence as
described by Rius et al^3^ based on the GenBank sequence AF035753, was not
screened in my work, it had previously been screened, in the families in my work, by
Shovlin et al^?
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3.3. FORTUITOUS OUTCOME OF PRIMER GW8
MISANNEALING
As mentioned above, primer GW8 was designed to sequence the 3' end of the GW1
and 7 product as it started 23 base pairs upstream ofGW7 and was an antisense
primer. The sequence obtained with it however was completely different to the
expected sequence. When the sequence obtained was checked by the BLAST
programme from The National Center for Biotechnology Information (NCBI),
website http://www.ncbi.nlm.nih.gov/, it was found to be identical to sequence just
downstream ofGW1. Knowing the site of the sequence that had been obtained, it
was possible to deduce the region where GW8 must have misannealed. In the
expected site, using comparison by eye, ten base pairs (TGTCACTGCC) had
identical sequence to that of the area for which GW8 had been designed, suggesting
that this was likely to be the position ofmisannealing. The site ofmisannealing was
the antisense strand starting 199 base pairs downstream of the 5'end of the GW1 and
7 fragment (see Figure 3.1). The region from the site of the misannealing to the 5'
start of the GW1 and 7 PCR product had therefore been sequenced with this primer.
The results of the misannealing were interesting. One individual, individual 54 from
family D, one of the families which was too small to allow linkage to endoglin to be
rnade^?, showed dual sequence compared to the other individuals (see Figure 3.6).
This appeared to be due to a 2 base pair deletion in one of the alleles. When
sequencing the same region in the other direction using primer GW5, a nested primer
to GW1 starting 9 base pairs downstream ofGW1, dual sequence was again seen just
in individual 54, again due to a 2 base pair deletion. Without separating the two
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alleles for individual 54 it was difficult to pinpoint the exact site of the deletion
although it was thought to be within 65 base pairs of the 5' end of the GW1 and 7
fragment. Therefore a small PCR product of 128 base pairs (126 base pairs if the
deletion was present) was produced using primers GW1 and GW10 which
encompassed the region of interest. This was successfully cloned (see Figure
3.7)(see Section 2.7) thus separating the two alleles. The cloned product was
sequenced with primer GW10. This showed a 2 base pair CA deletion in 2 of the 10
clones, 46 and 47 base pairs respectively downstream of the 5' end of the GW1 and 7
fragment i.e. 2564 and 2563 base pairs upstream of the transcription start site (See
Figure 3.8 and Figure 3.9).
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3.4. FAMILIAL SEGREGATION OF POLYMORPHISM
To determine whether or not this CA deletion polymorphism cosegregated with
disease in this pedigree, DNA from the other individuals in the family was then
analysed (see Figure 3.10). A small PCR product encompassing the site of the
deletion was obtained for individuals 53, 55, and 56, as well as further product for
individual 54. Unfortunately the only way to obtain product was from a nested
reaction using DNA amplified by primers GW1 and 10, as target DNA for a further
50 pi Tth/vent reaction using a nesting sense primer GW5, starting 9 base pairs
downstream ofGW1, and primer GW10. This meant that 60 PCR cycles in total
were used. The presence or absence of the deletion in each individual was then
assessed by analysing the PCR product by restriction endonuclease digests and cycle
sequencing.
3.4.1. RESTRICTION ENDONUCLEASE DIGESTS TO ANALYSE FAMILY
D
Restriction endonuclease digests of the GW5/10 PCR product for all family D
individuals was performed (see Figure 3.11) with Xbal to confirm that the correct
PCR product was being analysed and with BsrI to detect the deletion.
3.4.1.1. XBAI RESULTS
The GW5/10 product should be digested into fragments of 76 and 44 base pairs
irrespective of whether or not the deletion is present. At first sight (see Figure 3.11)
the expected digestion appeared to have occurred. However, on further inspection,
the larger fragment was seen to be different in size in different individuals making
the results impossible to interpret.
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3.4.1.2. BSRI RESULTS
The deletion should abolish the BsrI restriction site so that a complete undigested
118 base pair product would be seen. If no deletion were present, digestion would
occur giving two fragments of 83 and 37 base pairs in length. As can be seen in the
gel in Figure 3.11, it appeared that digestion occurred in individual 53 but not in the
other individuals suggesting that individual 53 was the only member of the family
without the polymorphism. This again was inconclusive however because in
individual 54, known to be heterozygous for the polymorphism and therefore having
one wild type allele instead of two, no digested wild type allele was observed. This
implied that the digestion might have failed. Alternatively, it is possible that the
mutant allele had been preferentially amplified by the PCR. The GW5 and 10 PCR
products for all family D individuals were therefore then cycle sequenced instead.
3.4.2. CYCLE SEQUENCING TO ANALYSE FAMILY D
The GW5 and 10 PCR products for all family D individuals were sequenced using
GW16, a primer nested to GW10 starting 15 base pairs upstream of GW10 and
acting on the antisense strand. This demonstrated that individuals 54, 55, and 56 had
the deleted and normal alleles whereas individual 53 only had the normal alleles.
This meant that the CA deletion was passed from the affected mother (individual 54)
to the affected daughter (individual 56). However the deletion was also seen in the
unaffected spouse of the daughter (individual 55) and so this indicated that it must be
a polymorphism not a disease-causing mutation (see Figure 3.12).
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3.5. TRANSCRIPTION FACTOR BINDING SITES DISRUPTED
BY THE CA DELETION
To assess whether or not this polymorphism could have any effect on function,
potential transcription factor binding sites which could be encoded by this region,
and so be disrupted by the deletion, were searched for using computer programmes
designed to test for transcription factor binding sites. Using Matlnspector V 2.2.
high similarity was found between this region and sequence encoding the retroviral
oncogene viral myb, and the transcription factor gut-enriched Kruppel-like factor
(GKLF). However other programmes, designed using more recent consensus
sequence, did not detect the same similarities. Close inspection of the sequences
from primary references indicated that there was insufficient homology for function
to be possible.
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3.6. ALLELE FREQUENCY OF THE POLYMORPHISM
To determine the allele frequency in the UK population of this polymorphism, 100
normal chromosomes were analysed. DNA from 50 unaffected spouses was
amplified in the same way as previously with PCR product from a GW1 and 10
primed reaction being used as target DNA for a GW5 and 10 primed reaction. The
product was sequenced with GW16. The polymorphism was seen in 8 of the 50
individuals, occurring in both alleles in one of them. This gave an allele frequency
of 9% for this polymorphism (see Figure 3.13).
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3.7. SUMMARY
In the families analysed no mutations in the endoglin promoter region were found
that could account for disease in endoglin-linked families. The promoter region was
fully sequenced in both directions in affected individuals from the 8 families
identified with no mutation or polymorphism seen. This cannot fully discount the
hypothesis that mutations in the endoglin promoter region could account for disease
in endoglin-\inked families as only a small number of families were analysed.
A two base pair CA deletion was found 2563 base pairs upstream of the transcription
start site in an affected individual from one of the fami lies. It was found to
cosegregate with disease but was also seen in the unaffected spouse of the affected
daughter indicating that it was a polymorphism rather than a mutation. It has been
shown to have an allele frequency of 9% in the UK population.
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REGION AROUND THE ENDOGLIN PROMOTER AND



















§ E Primers used, and direction they act in, are
O
> indicated by solid black arrows. The number
~t * cd below the long box represents the base pair number
——J-1 with respect to the major transcription start site at




FIGURE 3.2 PCR PRODUCTS USING PRIMERS GW1 AND GW7 AND
GENOMIC TARGET DNA
Water Individuals
X Hind III control 13 28 52
Base
pairs
PCR product 2763 base pairs in length was obtained with primers GW1 and 7 and
genomic target DNA from affected individuals.
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FIGURE 3.3 RESTRICTION ENDONUCLEASE DIGEST WITH AVAI
AND PVUII OF PCR PRODUCT USING PRIMERS GW1
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The expected fragment lengths were obtained when GW1 and 7 PCR product was
digested with Aval and PVUII. This confirmed that GW1 and 7 had amplified the
region ofDNA for which they had been designed.
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PCR product 1596 base pairs in length was obtained with primers GW1 and 3 and
genomic target DNA from affected individuals.
Page 91












[ j Untranslated sequence
Sequence numbered as for AF035753
Primer endolF was derived from sequence 5' to the major transcriptional start
sequence and used in mutational studies by Shovlin et aP7 Primer GW7 was the
most 3' primer used in my work. Thus, although the region between the 5'
untranslated region of exon 1 as described by Shovlin et aP7, based on the GenBank
sequence X72012, and coding sequence as described by Rius et al*^ based on the
GenBank sequence AF035753, was not screened in my work, it had previously been
screened, in the families in my work, by Shovlin et aP?
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FIGURE 3.6 THE G TRACK OF SEQUENCE USING PRIMER GW8
243
Individuals
52 54 95 109
Termination of a shorter allele, k
as well as the normal allele,
seen in 54
Dual sequence seen in 54
from this point until the
termination, suggesting deletion
is in this region
Dual sequence was seen in affected individual 54 from family D when cycle
sequencing with primer GW8 on GW1 and 7 PCR product.
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FIGURE 3.7 COLONIES DIGESTED WITH ECORI TO OBTAIN
CLONED GW1/10 INSERT
Undigested
A small PCR product of 128 base pairs was produced using primers GW1 and 10 on
DNA from individual 54. This amplified the region where the deletion had been
detected previously. The product was cloned to separate the 2 alleles and the cloned
inserts were obtained by digestion with EcoRI.
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FIGURE 3.8 THE G TRACK OF 10 SEQUENCED CLONES
Clones
2 4 5 6 7 8 9 11 14 15
2 base pair deletion, one of which
is a g, occurring in clones 2 and
15 between the arrows
GW1 and 10 PCR product from affected individual 54 was cloned and the clones
sequenced with primer GW10. Two of the clones, numbers 2 and 15, showed a 2
base pair deletion.
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FIGURE 3.9 SEQUENCING GELS SHOWING G AND T BASES
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TdSSSfca.
Clone 2 Clone 9
(published sequence)
GW1 and 10 PCR product from affected individual 54 was cloned and the clones
sequenced with primer GW10. Two of the clones, numbers 2 and 15, showed a 2
base pair deletion. Looking at all four nucleotide tracks reveals that the deletion in
clone 2 is due to an absent T and G base (marked with the solid black arrows in clone
9). As the antisense strand was sequenced this is a CA deletion in the published
sense strand.
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The numbered family members are the ones which were analysed. Affected
individuals are indicated by black symbols, unaffected by white symbols, and the
individual with unknown disease status is in grey. Squares represent males and
circles represent females.
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FIGURE 3.11 RESTRICTION ENDONUCLEASE DIGEST WITH XBAI
AND BSRI OF PCR PRODUCT USING PRIMERS GW5





53 54 55 56
Digested with Bsrl
53 54 55 56
The region where the deletion had been found in individual 54 was amplified with
GW1 and 10 and then GW5 and 10 in other members of family D. The product was
digested with Xbal to confirm that the correct PCR product was being analysed. It
was then digested with Bsrl. If the deletion was present it should abolish the Bsrl
restriction site preventing digestion (see Section 3.4.1 for further details).
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The region where the deletion had been found in individual 54 was amplified with
GW1 and 10 and then GW5 and 10 in other members of family D. The product was
sequenced with GW16, a primer nested to GW10. This picture shows the
termination of the C track of sequence for each member of family D. Dual sequence
was seen in individuals 54, 55, and 56 with termination of a shorter, as well as a
normal length, allele. This indicated that the deletion had been passed from the
affected mother to the affected daughter but was also present in the unaffected
husband of the daughter. The deletion was therefore a polymorphism not a disease-
causing mutation.
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FIGURE 3.13 TERMINATIONS IN G TRACK SEQUENCINGWITH
GW16 ON GW5/10 PCR PRODUCT TO ASSESS ALLELE
FREQUENCY OF POLYMORPHISM
The allele frequency in the UK population of the CA deletion polymorphism was
calculated by amplifying DNA from 50 unaffected spouses with PCR product from a
GW1 and 10 primed reaction being used as target DNA for a GW5 and 10 primed
reaction. The product was sequenced with GW16. The polymorphism was seen in 8
of the 50 individuals (termination of a shorter allele as well as the normal allele is
demonstrated in this gel), occurring in both alleles in one of them. This gave an
allele frequency of 9% for this polymorphism.
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4. LINKAGE
Hypothesis: HHTfamilies withpulmonary involvement may he unlinked to the
PA VMgene, endoglin, andmay be unlinked to both known HHTgenes, endoglin and
ALK1
This hypothesis was suggested by two pieces of evidence. First, the work of an
Italian group suggests that a third gene for HHT could exist140^ although no
pulmonary involvement was seen in the pedigree described by this group. Secondly
PAVMs have been shown not to occur exclusively in e«<iog//«-linked families^ 37^
although ALK1 status was unknown.
As stated previously families S and P, initially identified in 1992 when one
individual from each presented to the Hammersmith Hospital for management of
PAVMs, were assessed further by myself and CLS six years later. They were
considered as being suitable for testing the above hypothesis as they had pulmonary
involvement and initial analyses in 1992 suggested that they were unlinked to
endoglin, but there were insufficient numbers to allow ALK1 linkage analyses35.
Clinical evaluation, venepuncture, DNA extraction, and linkage analyses were
performed for each individual as described previously.
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4.1. FAMILY S
4.1.1. RESULTS OF CLINICAL EVALUATION
The pedigree for family S is shown in Figure 4.1 with the results of the clinical
investigations in Table 4.1. Family members who were not assessed are not shown.
Table 4.2 shows that overall 11 new diagnoses were made, 3 in original members
who had now reached phenotypable age, and 8 from the 10 additional members
assessed. Four generations were assessed with 12 affected members identified from
all generations. Individual IV.3 was given a diagnosis of obligate affected as she had
affected offspring and also an affected parent, but her only manifestation was
epistaxis. Individuals V. 1, V.5, and V. 11 had epistaxis only but no affected children
and so were classified of unknown status and excluded from further analysis.
Individual IV.3 had a geographical and fish tongue.
4.1.1.1. FAMILY S MEMBERS WITH A DIAGNOSIS OF PAVMS
As mentioned in Section 2.1.2.1, individuals were suspected of having PAVMs based
on haemoptysis, central cyanosis, or clubbing, Sa02 erect < 96% (as recommended
byl or supine-erect fall greater than 3.3% (thus exceeding 2SDs beyond the
mean of 0.3% (SD1.5) in the non-PAVM group inl ^). Individual V.3 fulfilled
these criteria by having an erect Sa02 of< 96% and individual V.4 fulfilled the
criteria by having a supine-erect fall in Sa02 of 4%. Individual IV.2 also fulfilled
the criteria by having an erect Sa02 of< 96%. He declined further investigation for
PAVMs however.
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4.1.1.2. FURTHER DETAILS OF FAMILY S MEMBERS WITH A
DIAGNOSIS OF PAVMS
Individual V.3 was the proband for this family, and had presented aged 23 years with
a long-standing history of painless haemoptysis and a one year history of episodic
dizziness and blurred vision. He was not dyspnoeic. Examination revealed bilateral
early clubbing and a bruit was audible over the right lower lobe. He was
polycythaemic (Hb 18.9, haematocrit 0.55), and hypoxaemic (pH 7.44, pC02
4.5kPa, p02 8.2kPa) with additional orthodeoxia (supine Sa02 92%, erect 87%).
Spirometry was normal (FEV1 5.25 litres, FVC 5.95 litres) but the gas transfer was
markedly reduced with TLCO 6.96 (52% predicted), KCO 1.87 (51% predicted).
Chest X-rays and a thoracic CT scan confirmed the presence of several PAVMs. The
right-to-left (R-L) shunt measured by "mTechnetium-labelled albumin
macroaggregates was 24% of the cardiac output. Following selective right
pulmonary angiography, two large PAVMs were embolised with 21 steel coils
resulting in immediate improvement in oxygen saturations (supine Sa02 97%, erect
96%). His initial family screening dates from this period. The improvement in Sa02
was sustained two years post embolisation. The R-L shunt remained at 4.2%,
probably accounted for by a residual right basal PAVM with feeding arteries too
small to embolise. When we assessed him 6 years post embolisation his dizzy spells
had recurred, oxygen saturations fell to 96% supine, 95% erect. His haematocrit was
mildly raised at 0.564 (normal range 0.40-0.54) but his haemoglobin was normal at
165g/l. He is due to be re-evaluated with further pulmonary angiography.
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Individual V.4 had been first evaluated as part of a family screen (by CLS) at the age
of 21 years when she had no epistaxes or telangiectasia and normal oxygen
saturations (Sa02 100% in supine and erect postures). When reviewed by CLS and
myself for this study, she was aged 27 years, and was 10 months post partum. She
described the development ofmonthly epistaxes and frequent dizzy spells after her
pregnancy. On examination, she was not clubbed or cyanosed, but she demonstrated
significant desaturation in the erect posture (Sa02 99% supine, 94% erect). Her
subsequent review five months later by respiratory physicians, following our
recommendation to her general practitioner, indicated that her hypoxaemia had
persisted (Sa02 97% supine, 93% erect, 92% post 90 watts of exercise). Her
haematocrit was raised at 0.515 (normal range 0.37-0.47) but her haemoglobin was
normal at 148g/l. Spirometry was normal (FEV1 4.00 litres, 117% predicted; FVC
4.3 litres, 109% predicted), but the gas transfer was marginally impaired (KCO,
corrected for Hb, 1.59, 88% predicted). Contrast echocardiography indicated the
presence of a R-L shunt, though a thoracic CT scan (axial scanning at 5mm intervals)
did not reveal any macroscopic PAVMs. A diagnosis ofmicroscopic PAVMs was
made. On review six months later, her oximetry showed spontaneous improvement
at rest (Sa02 98% in supine and erect postures) but post-exercise oximetry and gas
transfer remained marginally impaired (Sa02 96% following 120 watts of exercise;
corrected KCO 1.55, 85% predicted), and radionucleotide scanning quantitated the
R-L shunt at 7.2% of the cardiac output (normal < 3.5%). She remains on




4.1.2.1. EXCLUSION OF ENDOGLIN
The position ofendoglin relative to the polymorphic markers used is shown in Figure
4.2. The HHT1 locus was originally mapped to a 2cM interval on chromosome 9
flanked by D9S60 and D9S6135. The adjacent D9S61-D9S63 interval was suggested
by other investigators^ but later revised by the same group to between D9S60 and
D9S61136 The endoglin gene has been mapped physically as equidistant between
D9S315 and SPTANwhich both lie within the interval flanked by D9S60 and D9S61.
The relative positions of endoglin and AK1 have not been resolved. Markers D9S60,
D9S315, and D9S61 were initially used.
Two point lod scores obtained with markers D9S60, D9S315, and D9S61 were
sufficient to exclude linkage to endoglin in family S (see Figure 4.3). Using the
definition of a score of -2 or less indicating no linkage at a significance level of 0.05,
these data exclude linkage to a region of about 15 cM on both sides of the endoglin
locus. This is also demonstrated by multipoint analysis (see Figure 4.3).
4.1.2.2. EXCLUSION OF ALK1
Analysis of linkage to ALK1 was performed. Figure 4.4 shows the location ofALK1
relative to its flanking polymorphic markers. Two original assignments of the HHT2
locus were given, one between D12S339 and D12S359137, and the other in a
neighbouring interval between D12S345 and D12S339^% (marked with a broken
line in Figure 4.4). The latter was revised on subsequent analyses and the ALK1
gene is now known to lie in the 4cM interval between D12S347 and D12S359
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(marked with a solid black line with grey extension in Figure 4.4), most likely in the
lcM interval between D12S347 and D12S368^^(marked with a solid black line in
Figure 4.4). Nevertheless I considered it prudent to examine both disease intervals
using markers D12S331, D12S85, D12S347, and D12S368 initially.
In family S marker D12S368 did not exclude linkage to the region flanked by it and
D12S325 (see Figure 4.5), although the region between it and D12SS331 was
excluded. Marker D12S325 was therefore analysed. Lod scores obtained for it were
sufficiently negative to exclude linkage to the D12S368-D12S325 region. Two point
lod scores therefore excluded ALK1 linkage in family S and this exclusion was
further confirmed by multipoint analysis for these markers in family S (see Figure
4.5).
4.1.3. ALLELE FREQUENCIES
Lod scores were initially analysed using equal allele frequencies. Some of the
markers were reanalysed using altered allele frequencies reflecting the frequencies
seen in the pedigree studied. This did not significantly alter any of the lod scores
obtained (see Table 4.3).
4.1.4. HAPLOTYPE ANALYSES
Limited haplotype analyses in families S were performed.
In family S, on both chromosome 9 and chromosome 12, of the four affected
individuals in generation IV (three ofwhom were parents or grandparents of affected
individuals so must have been correctly phenotyped), two displayed one haplotype
which could be traced to their affected parent and two the other. Analysis of the
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haplotypes transmitted to and by the individuals with proven PAVMs (V.3, V.4),
who clearly also have the correct disease status assignment, was particularly
instructive (see Figure 4.6). It can be seen that on both chromosomes 9 and 12, both
V.3 and V.4 have inherited the haplotype (B) from their affected mother that she
inherited from her unaffected father (with a recombination event between D12S85
and D12S347 in V.4 on chromosome 12). Moreover, on both chromosomes, V.3 has
transmitted to his affected daughter (VI. 1) the haplotype that he inherited from his
unaffected father (C). This confirms that HHT in this family cannot result from
mutations in either endoglin or ALK1.
4.1.5. SUMMARY




4.2.1. RESULTS OF CLINICAL EVALUATION
The pedigree of family P is shown in Figure 4.7 along with the results of the clinical
investigations in Table 4.4. Family members who were unavailable for assessment
are not shown. As shown in Table 4.2, 2 new diagnoses were made in original
members due to these members reaching phenotypable age, and 20 additional
members were assessed enabling 17 further new diagnoses. In total, 19 new
diagnoses were made. 24 members spanning 4 generations were affected by HHT as
defined by the consensus criteria^9 Individuals III. 1, IV.9, and IV. 10 were
classified as obligate affected as they all had affected offspring although personally
fulfilled only two diagnostic criteria. Individuals V.4 and V. 10 had epistaxis only
and no affected children. They were categorised as being of unknown status and
further analysis was not performed. Individual IV. 13 had no epistaxis. She had
possible telangiectasia but they were difficult to distinguish from spider
telangiectasia and she had a history of heavy alcohol usage. Her son, individual V. 15
had several episodes of epistaxis each year but this was possibly traumatic in nature.
He had only a possible telangiectasia and no affected offspring. They were both
therefore also classified as being of unknown status and not analysed further. It
would be interesting to obtain a CT head scan for individual V. 15 given his history
of epilepsy, as this could possibly be due to HHT related CAVMs. Strictly speaking,
however, even if a diagnosis ofCAVMs was confirmed, this would still not be
enough to allow disease status to be assigned to him or his mother229 individual
V.3 had a large telangiectatic lesion on her thumb during the third trimester of her
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pregnancy which improved markedly after the delivery of her daughter. It is possible
that her pregnancy had also worsened or precipitated PAVMs. Her oxygen
saturations were worse postpartum probably since the pregnancy had masked PAVM
associated hypoxaemia. She had had normal oxygen saturations 6 years previously.
In contrast individual IV. 5 demonstrated the often deleterious effect that a low
oestrogen state has on HHT since her epistaxis had become more severe, and she had
started to have GI bleeds (although the cause is unknown), since the menopause.
Individual IV. 5 had a fish tongue and individual V.7 had a geographical tongue.
These features have not been associated with HHT previously and could, of course,
be incidental, but it is interesting to note that one of the affected individuals from
family S (individual IV.3) had a geographical and fish tongue.
4.2.1.1. FAMILY P MEMBERS WITH POSSIBLE PAVMS
The same criteria for PAVM screening (see Section 2.1.2.1) as when screening
family S members were used to screen family P members. Individual V.3 had an
erect Sa02 of< 96% post partum and individual V.5 also had an erect Sa02 of<
96% and was clubbed. Individual III. 1 was suspected of having PAVMs on clinical
examination alone (clubbing) and individuals V.7, VI. 1, and VI.3 were suspected on
clinical history alone (haemoptysis). Further investigation for PAVMs was therefore
recommended for all of these: some declined follow up and the remainder are under
review by local respiratory physicians.
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4.2.2. LINKAGE ANALYSES
4.2.2.1. INCONCLUSIVE ENDOGLIN LINKAGE DATA
The position of endoglin relative to the polymorphic markers used is shown in Figure
4.2. The HHT1 locus was originally mapped to a 2cM interval on chromosome 9
flanked by D9S60 and D9S6135. The adjacent D9S61-D9S63 interval was suggested
by other investigators^ but later revised by the same group to between D9S60 and
D9S61 * 36 The endoglin gene has been mapped physically as equidistant between
D9S315 and SPTANwhich both lie within the interval flanked by D9S60 and D9S61.
The relative positions of endoglin and AK1 have not been resolved. Markers D9S60,
D9S315, and D9S61 were initially used.
Lod scores obtained for markers D9S60, D9S315, and D9S61 did not suggest linkage
to the endoglin locus between D9S315 and D9S61 (if the disease gene in this family
were linked to endoglin, markers D9S60, D9S61 and D9S315 would be expected to
show strongly positive lod scores at low recombination values at 9<0.0235).
However, in contrast to Family S, positive lod scores were obtained with some of
these markers (see Table 4.5). The significantly positive lod scores obtained with
marker D9S61 could not be interpreted as excluding linkage to endoglin. In
particular the score of 1.27 at 0 = 0.2 with marker D9S61, indicated that the regions
20-30 cM from the region spanned by the three markers should be analysed further.
Further markers were therefore studied to clarify this (see Table 4.6). Significantly
positive lod scores were again obtained with marker HXB, but there was no
consistent pattern to confirm or refute linkage to the region.
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4.2.2.1.1. HAPLOTYPE ANALYSES
Given the inconclusive data obtained for family P when assessing endoglin linkage
using two point analyses, I attempted to obtain additional information by performing
haplotype analyses of chromosome 9 markers. Data was converted using Mega 2^33
and analysed using Simwalk2234 both via HGMP computational facilities. Limited
analyses using HXB, D9S60, D9S315, and D9S61 indicated that there were three
potential haplotype solutions preventing the derivation of additional data by this
method. Figure 4.8 illustrates allele inheritance for the purposes of discussion of
allele frequencies in the pedigree.
4.2.2.1.2. MODELS CONSTRUCTED FOR INCONCLUSIVE ENDOGLIN
LINKAGE DATA
Three possible models were constructed for this inconclusive data: firstly that family
P was linked to endoglin and that the method did not detect this linkage, secondly
that the disease gene lay approximately 20-30cM away, and thirdly that the family
was unlinked to both endoglin and neighbouring markers and spuriously high lod
scores had been obtained with some of the markers.
4.2.2.1.2.1. MODEL 1: ANALYSES HAVE FAILED TO CONFIRM
LINKAGE IN AN ENDOGLIN-LTNKED FAMILY
If the disease gene in this family were linked to endoglin, markers D9S60, D9S315,
and D9S61 would be expected to show strongly positive lod scores at low
recombination values of 0 < 0.0235. Negative lod scores at low values of 0
hypothetically could have arisen by one of a number of potential limitations of
linkage analyses as discussed in the introduction (see Section 1.5.5). Specifically:
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1) Misphenotyping- The negative lod scores within 1-2 cM of the endoglin gene
could have resulted from misphenotyping of genetically unaffected individuals as
affecteds, as in this setting theMLINK program assigns a probability of 1.0 that
the assigned phenotype is correct. This is in contrast to an unaffected diagnosis
which is made with <100% confidence (defined in our age-related penetrance
model as being at probabilities of 0.8 at ages 12-35 and 0.95 at ages >35).
Probands 1V.3, IV.5, IV.7 and V.8 are concordant across D9S60-61, but IV. 1
could only be concordant at D9S60 (see Figure 4.8). As endoglin lies between
D9S315 and D9S61, that would imply IV. 1 and descendants (V.2, VI. 1, and
VI.2), III. 1 and descendent (IV. 12) and V.7 would all have had to be
misphenotyped. This possibility was considered carefully, particularly as none of
these individuals had documented visceral involvement (although of note VI. 1
had haemoptysis when running, III. 1 was clubbed, and V.7 had haemoptysis
daily for 4 months) (see Table 4.4). It must be noted that III. I did not have
epistaxis and was designated obligate affected due to having telangiectasia and an
affected offspring (IV. 12) according to the current international consensus
criteria^ 17. All of the other probands had epistaxis and they all, including III. 1,
had telangiectasia. While spontaneous nosebleeds can occur in non-HHT
patients, a non-HHT cause of classical HHT telangiectasia cosegregating with
disease in this family to result in these misdiagnoses would be highly unlikely,
but remains hypothetically possible. Therefore misphenotyping to generate
artificially negative lod scores could only have occurred ifwe were to postulate
the unlikely scenario of a second condition (genetic or environmental)
contributing to these clinical features in these probands.
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2) Incorrect assignment of parentage- Although it is hypothetically possible that
non-parentage could have contributed, this would require the affected father of
IV. 1 to be different to the affected father of IV.3, IV.5, and IV.7, and neither of
these fathers to be the brother of III. 1. IV.7 would also not be the father ofV.7
who would have a different affected father. This is highly unlikely. In any case
there was no evidence of non-parentage in this family as in all markers studied
expected Mendelian segregation was seen (see Section 1.5.5.2).
Conclusion: This model does not appear likely. Furthermore it should be noted that
endoglin mutational analysis has been conducted on 2 probands in the pedigree (IV.7
and V.8) and indicated no evidence for mutations in the genomic DNA (Southern
blotting, cycle sequencing of all known exons and intronics on junctions) or cloned
DNA^7 supporting the conclusion that endoglin is unlikely to be the disease gene in
this family.
4.2.2 1 2.2. MODEL 2: IN FAMILY P THERE IS A NOVEL HHT DISEASE
GENE SITED APPROXIMATELY 20-30CM AWAY FROM THE ENDOGLIN
LOCUS
The significantly positive lod scores obtained with marker HXB were not obtained
with the other markers in the vicinity, markers D9S26J, D9S289, and D9S195, which
demonstrated lod scores of-2.30 at 0 = 0.05, -7.37 at 0 = 0.00, and -3.33 at 0 = 0.01
respectively (see Table 4.6). Normally, such findings would be taken to exclude
linkage but the model in question demands that we should consider whether or not
the analyses ofD9S261, D9S289, and D9S195 could be spurious. Possible causes for
this could include:
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1) Incorrect siting ofmarkers on the genetic map so that distances are
inappropriately low between these markers. This would have been a significant
concern in the early days of linkage mapping, but is less likely given the
extensive work by Genethon232 anc| other investigators that went into siting
these markers. It is particularly unlikely since HXB lies in the middle of the
markers, between D9S289 and D9S195. Since recombination mapping using
Genethon pedigrees was used to site the markers, errors in order are significantly
less likely than errors in distance, as this would require frequent double
recombinations in small genetic distances between two adjacent markers.
2) Sample mix-up. A key feature ofmy laboratory training was to take judicious
care never to mix up samples at any stage ofDNA preparation or analysis.
Nevertheless the possibility will be discussed to assess whether this was feasible
based on the results. If samples had been mixed up when working with markers
D9S261, D9S289, and D9S195, but not when working with marker HXB, this
could produce the results obtained in this work. However this would mean that
for marker D9S261 the key "mixed up" samples would be for individuals III. 1,
IV. 11, IV. 12, and V.7 whereas for markers D9S289 and D9S195 samples for
different groups of individuals would need to be mixed up (III. 1, IV. 1, IV. 12,
V.2, VI. 1, and VI.2 for D9S289-, III.l, IV. 10, IV. 12, V.7, and V.12 for D9S195)
(see Figure 4.8). Furthermore it should be noted that it is often an individual plus
the individual's affected descendants whose samples would need to be mixed up
rather than random individuals' samples e.g. the samples for IV. 1 plus all her
descendants would need to be mixed up when marker D9S289 was used. Sample
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mix up is rendered even less likely as non-Mendelian patterns of inheritance of
marker alleles would result and this was not seen.
Conclusion: From the data in this thesis alone, linkage to this region of chromosome
9 cannot be excluded. While HXB in itself is not a good candidate, there are other
candidates in the region including the type 1 TGFB receptor, ALK-5. Further linkage
studies are underway in the Shovlin laboratory and the results are awaited.
4.2.2.1.2.3. MODEL 3: THERE IS NO HHT DISEASE GENE IN THE
REGION ON CHROMOSOME 9. THE D9S61 AND HXB LOD SCORES ARE
SPURIOUSLY HIGH AS A RESULT OF COMMON ALLELES PRESENT IN
THE POPULATION APPARENTLY SEGREGATING WITH DISEASE
In this setting we should consider whether the lod scores for markers HXB and
D9S61 are artificially high. For HXB this possibility could arise if the allele shared
at HXB by IV. 1, IV.3, IV.5, and IV.7, (designated allele 1), is common in the general
population and the affected father of IV. 1, IV.3, IV.5 and IV.7 was homozygous for
allele 1. Although the heterozygosity index for HXB is 0.79, it could be lower in this
particular population. Since two of the ten spouses' alleles (from IV.2, IV.4, IV.6,
IV. 8, and V. 1) are allele 1, this very limited survey indicates this might be a
relatively common allele in the local population, and the possibility that the affected
father of IV. 1, IV.3, IV.5 and IV.7 was homozygous for allele 1 must be considered.
The fact that his sister was homozygous for allele 5 does not exclude this possibility.
Similar considerations can be applied to discussions of the positive lod scores with
D9S61.
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The possession of particular alleles by non-affected spouses was specifically
analysed to investigate the possibility that artificially high lod scores might be
generated by their bringing the allele designated as "disease" allele into the pedigree.
For all the markers, except GSN, ABL, and D9S66, at least one of the five unaffected
spouses carried the allele shared by affected individuals IV.3, IV.5, and IV.7.
Conclusion: Model 3 is plausible.
4.2.2.1.2.4. CONCLUSIONS FROM THE MODELS
It can be seen from these three models that the data remains inconclusive although
the most likely model appears to be the third one- that the family is unlinked to both
endoglin and neighbouring markers and spuriously high lod scores were obtained
with some of the markers.
4.2.2.2. EXCLUSION OF ALK1
Analysis of linkage to ALK1 was performed. Figure 4.4 shows the location ofALK1
relative to its flanking polymorphic markers. Two original assignments of the HHT2
locus were given, one between D12S339 and D12S359^, and the other in a
neighbouring interval between DJ2S345 and D12S339138 (marked with a broken
line in Figure 4.4). The latter was revised on subsequent analyses and the ALK1
gene is now known to lie in the 4cM interval between D12S347 and D12S359
(marked with a solid black line with grey extension in Figure 4.4), most likely in the
lcM interval between D12S347 and D12S368^9(marked with a solid black line in
Figure 4.4). Nevertheless I considered it prudent to examine both disease intervals
using markers D12S331, D12S85, D12S347, and D12S368 initially.
Page 116
Two point lod scores obtained for family P (see Table 4.7) significantly excluded
linkage to ALK1. Although marker D12S325 was not analysed in this pedigree,
results obtained with marker D12S368 significantly excluded linkage to a region
extending to about 18 cM from it and so easily excluded the region flanked by
D12S325.
4.2.3. ALLELE FREQUENCIES
Lod scores were initially analysed using equal allele frequencies. Some of the
markers were reanalysed using altered allele frequencies reflecting the frequencies
seen in the pedigree studied (see Table 4.8). This did not significantly alter any of
the lod scores obtained (see Table 4.9).
4.2.4. SUMMARY
Family P is an HHT family with probable pulmonary involvement which is unlinked
to ALK1 but the data regarding endoglin linkage is inconclusive.
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4.3. FAMILIES V AND T- ASSESSMENT OF ALKl LINKAGE IN
KNOWN NON-ENDOGLINHHT-PAVM FAMILIES
Two additional HHT families with pulmonary involvement, families V and T, had
previously been reported as being unlinked to endoglin^ (No positive lod scores
obtained for either family; family V: Z= -2.58, 0= 0.00, D9S315 ; family T: Z= -2.06,
0= 0.01, D9S61). No mutations had been found by Southern blotting of the entire
endoglin gene, cycle sequencing of all known exons and intron/exon junctions, and
cycle sequencing of the entire cloned DNA^. DNA obtained when the families
were clinically assessed in 1992 was used for analysis. The families were not
assessed further clinically by myself. The family trees for families V and T are
shown in Figure 4.9. Individual III. 1 from family V had a PAVM (25% R-L shunt at
presentation with associated clubbing). Individual III.4 from family T had a
symptomatic PAVM (R-L shunt 15.5% at presentation). I hypothesised that in these
families HHT could result from either a mutation in the ALK1 gene (not previously
associated with HHT leading to the development ofPAVMs) or that they could
represent further families unlinked to the known HHT genes endoglin and ALK1.
Six years ago they had also been assessed for ALKl linkage with no significant
results obtained. However since then the disease interval has been refined allowing
markers much closer to ALKl to be used and so increasing the likelihood of




Two point lod scores obtained with D12S368 exceed +1.2 over the interval spanning
the ALK1 locus, and a possible extension if earlier, now superseded work, was
current137" 139 This indicates significant linkage to the known ALK1 locus in
family V. In the course of this project, due to time constraints, I was unable to
pursue this to identify the causative ALK1 gene mutation.
4.3.2. FAMILY T
In family T the negative two point lod scores obtained with DJ2S368 suggested that
this family could be a non-endoglin, non-ALK1 HHT-PAVM family, but the scores
with this marker, and the adjacent marker D12S339, were insufficiently informative.
In the course of these studies there was insufficient time to pursue these analyses
further.
4.3.3. SUMMARY
Family V is an HHT-PAVM family linked to ALK1. Family T is an HHT-PAVM
family unlinked to endoglin with inconclusive ALK1 linkage data.
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4.4. CONCLUSIONS
1. These results demonstrate that not all HHT families with pulmonary involvement
are linked to the known HHT-PAVM gene, endoglin, and furthermore that one
family, family S, is unlinked to the two known HHT genes, endoglin and ALK1.
2. The most important finding is that family S, an HHT-PAVM family, is unlinked
to the two known HHT genes, endoglin and ALK1. Since endoglin and ALK1 are
both involved in the regulation of response to ligands of the TGF(3 superfamily, it
seems likely that the gene mutated in family S may encode another component of
the TGFp signalling complex or a downstream effector. Its identification should
significantly enhance our understanding of signalling by TGFP family members.
The finding also has an immediate clinical implication since it is clear from this
work that all HHT families, not just endoglin-\\vk.Q& families, require PAVM
screening.
3. The linkage of an HHT-PAVM family, family V, to ALK1 indicates that PAVM
screening should be performed in ,41X7-linked families. This reinforces the
implication regarding PAVM screening derived from the family S data.
4. The inconclusive nature of the analyses in family P highlights some of the
limitations of linkage analyses. The modelling of theoretical possibilities was a
useful exercise to critically analyse the methodology and physical basis of
linkage studies.
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TABLE 4.1 CLINICAL FEATURES OF FAMILY S




m.i 76 - - - ANPS 97 97 Unaffected
m.2 69 childhood occasional buccal ANPS 98 97 Affected
III. 3 72 - - - ANPS - - Spouse
IV. 1 45 - - - ANPS - - Spouse
IV.2 49 childhood none lips, facial 96 96 Affected
IV. 3 48 childhood none since
cauterised aged
16
ANPS 98 97 Obligate
affected
IV.4 50 - - - ANPS - - Spouse
IV.5 48 childhood 2 monthly facial ANPS 100 100 Affected
IV.6 48 - - - ANPS - - Spouse
IV.7 42 childhood frequent, several
cauterisations
lips, buccal ANPS 98 98 Affected
IV.8 40 - - - ANPS - - Spouse
V.l 20 childhood occasional ?buccal, ?arms ANPS 97 97 Unknown
V.2 36 - - - ANPS - - Spouse




V.4 27 aged 26 monthly lips, hands "dizzy spells" 98 94 Affected
V.5 22 childhood none since
childhood
- ANPS 99 96 Unknown
V.6 19 childhood occasional buccal ANPS 99 98 Affected
V.7 17 childhood weekly buccal ANPS 99 98 Affected
V.8 9 aged 4 several each
year
tongue, hand ANPS 98 98 Affected
V.9 18 childhood occasional buccal ANPS 98 98 Affected




ANPS 98 98 Unknown
VI.1 9 preschool several each
year
facial, fingers ANPS 98 97 Affected
*=prepartum **=postpartum ***= no blood sample obtained
Clinical: positive features of respiratory history and examination
ANPS= asymptomatic, no physical signs S= supine E= erect
Pedigree numbers correspond to Figure 4.1. See text for additional clinical information about V.3 and
V.4. Method for PAVM screening was adapted from Thompson el afi ^ in which Sa02 in the erect
posture of< 96% gave a sensitivity of 73% and specificity of 35%, for detection ofPAVMs as defined
by selective pulmonary angiography, and in which the supine-erect Sa02 was significantly greater in
the PAVM rather than non-PAVM group: 1.7% (SD 2.7) compared to 0.3% (SD1.5) p=0.01.
Therefore Sa02 erect < 96% or supine-erect fall greater than 3.3% (thus exceeding 2SDs beyond the
mean of 0.3% (SD1.5) in the non-PAVM group in 1 was used to suggest possible PAVMs
requiring further investigation.
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TABLE 4.2 DIAGNOSES OF HHT
Family S P
Total no. seen 23 36
No. of new members seen 10 20
Affected 11 21
Obligate affected 1 3
Unaffected 2 3
Unknown 3 4
Unaffected spouse 6 5
New Diagnoses in Original Members 3 2
New Diagnoses in New Members 8 17
Summary of number of family members of families S and P clinically assessed and
diagnoses made.
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TABLE 4.3 ANALYSIS OF LOD SCORESWITH EQUAL AND
ADJUSTED ALLELE FREQUENCIES IN FAMILY S
Family Locus Allele freq. Recombination fraction (0)
0.00 0.01 0.05 0.10 0.20 0.30 0.40 0.50
S D9S315 equal -16.07 -7.67 -4.93 -3.21 -1.57 -0.72 -0.25 0.00
s D9S315 adjusted -15.95 -7.60 -4.91 -3.19 -1.56 -0.72 -0.24 0.00
s D12S347 equal -9.07 -5.14 -4.60 -3.89 -2.16 -1.14 -0.47 0.00
s D12S347 adjusted -9.06 -5.14 -4.59 -3.80 -2.10 -1.13 -0.47 0.00
No significant difference was found between lod scores obtained using equal and
adjusted allele frequencies.
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TABLE 4.4 CLINICAL FEATURES OF FAMILY P










III.1 66 - - nasal, lip,
buccal
clubbed 97 97 TIAs Obligate
affected
IV. 1 61 ? Childhood none lips, buccal ANPS 97 97 - Affected
IV.2 62 - - - ANPS - - - Spouse
IV.3 58 childhood occasional facial, buccal,
hands
ANPS 97 97 - Affected
IV.4 62 - - - ANPS - - - Spouse
IV.5 54 childhood daily lips, buccal,
hands




IV.6 51 - - - ANPS - - - Spouse
IV.7 50 teenage daily despite
laser treatment
facial ANPS 98 98 - Affected
IV.8 53 - - - ANPS - - - Spouse
IV.9 55 - - lip ANPS 97 98 - Obligate
affected
IV.10 42 - - lip ANPS 97 98 - Obligate
affected




ANPS 97 97 - Affected
IV. 12 46 childhood weekly tongue ANPS 98 97 bright blood per
rectum
Affected
IV. 13 45 - - round lips
?ethanol related
ANPS 96 96 - Unknown
V.l 38 - - - ANPS - - - Spouse
V.2 38 childhood none since aged
10
buccal ANPS 96 98 - Affected













V.4 34 childhood several per year - ANPS 96 97 - Unknown
V.5 32 childhood twice weekly facial clubbed for 6
years
96 95 - Affected
V.6 29 - - - ANPS 98 98 - Unaffected






V.8 21 teenage monthly facial, fingers ANPS 98 98 - Affected
V.9 30 teenage several each
year
lips ANPS 97 97 - Affected




Continued on next page.
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V.ll 26 - - - ANPS 97 97 - Unaffected
V.12 16 aged 15 monthly lip ANPS 99 99 - Affected
V.13 13 - - - ANPS 97 98 - Unaffected




ANPS 98 97 - Affected
***
V.15 23 teenage 2-3 each year
but precipitated
by trauma
?top lip ANPS 96 96 epilepsy Unknown
VI. 1 14 childhood monthly nasal, buccal haemoptysis
when running
97/6 97/5 - Affected
VI.2 12 childhood several each
year
lip, hand ANPS 97 97 migraines Affected
VI. 3 17 childhood daily hands haemoptysis
every 2 weeks




VI.4 11 childhood several each
year
lip, hands ANPS 97 97 - Affected
VI.5 9 childhood monthly buccal, arms ANPS 98 97 - Affected
***
VI.6 12 preschool several each
year
hands ANPS 97 96 - Affected
***
VI.7 9 childhood several each
year
hands ANPS 97 97 - Affected
*=prepartum **=postpartum ***= no blood sample obtained
Clinical: positive features of respiratory history and examination
ANPS= asymptomatic, no physical signs S= supine E= erect
Pedigree numbers correspond to Figure 4.7. Method for PAVM screening was adapted from
Thompson et afi14 in which Sa02 in the erect posture of< 96% gave a sensitivity of 73% and
specificity of 35%, for detection ofPAVMs as defined by selective pulmonary angiography, and in
which the supine-erect Sa02 was significantly greater in the PAVM rather than non-PAVM group:
1.7% (SD 2.7) compared to 0.3% (SD1.5) p=0.01. Therefore Sa02 erect < 96% or supine-erect fall
greater than 3.3% (thus exceeding 2SDs beyond the mean of0.3% (SD1.5) in the non-PAVM group in
114) was used to suggest possible PAVMs requiring further investigation.
Page 125
TABLE 4.5 TWO POINT LOD SCORES FOR FAMILY P WITH






0.00 -17.14 -11.86 -6.27
0.01 -4.88 -3.79 -2.28
0.02 -3.40 -2.68 -1.71
0.03 -2.54 -2.01 -1.15
0.04 -1.95 -1.53 -0.70
0.05 -1.49 -1.17 -0.34
0.10 -0.21 -0.08 0.67
0.20 0.64 0.72 1.27
0.30 0.72 0.81 1.17
0.40 0.45 0.54 0.71
0.50 0.00 0.00 0.00
Lod scores were calculated at different recombination fractions.
Page 126
TABLE 4.6 TWO POINT LOD SCORES FOR FAMILY P WITH
ADDITIONAL CHROMOSOME 9 MARKERS
Locus Recombination fraction (0)
0.00 0.01 0.05 0.10 0.20 0.30 0.40 0.50
D9S261 -14.50 -5.76 -2.30 -1.82 -0.78 -0.32 -0.09 0.00
D9S289 -7.37 -0.77 0.47 0.83 0.90 0.67 0.35 0.00
HXB 1.48 1.45 1.33 1.17 0.81 0.44 0.11 0.00
D9S195 -17.17 -3.33 -0.32 0.69 1.17 0.94 0.44 0.00
GSN -14.23 -6.58 -3.08 -1.61 -0.42 0.00 0.09 0.00
D9S60 -17.14 -4.88 -1.49 -0.21 0.64 0.72 0.45 0.00
D9S315 -11.86 -3.79 -1.17 -0.08 0.72 0.81 0.54 0.00
D9S61 -6.27 -2.28 -0.34 0.67 1.27 1.17 0.71 0.00
ABL -19.34 -8.11 -3.69 -1.95 -0.55 -0.07 0.04 0.00
D9S66 -22.67 -5.40 -1.88 -0.55 0.37 0.53 0.36 0.00
D9S67 -7.91 -0.84 0.35 0.68 0.74 0.55 0.29 0.00
Lod scores were calculated at different recombination fractions. Endoglin lies
between D9S315 and D9S61.
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TABLE 4.7 TWO POINT LOD SCORES FOR MARKERS ADJACENT
TOALK1 IN FAMILY P
Locus Recombination fraction (0)
0.00 0.01 0.05 0.10 0.20 0.30 0.40 0.50
D12S331 -19.30 -7.40 -3.80 -2.24 -0.90 -0.34 -0.09 0.00
D12S85 -3.77 -3.46 -1.75 -0.98 -0.35 -0.10 -0.01 0.00
D12S347 -24.37 -7.21 -3.55 -2.08 -0.85 -0.32 -0.08 0.00
D12S368 -20.77 -10.46 -5.79 -3.72 -1.80 -0.87 -0.34 0.00
Lod scores were calculated at different recombination fractions.
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TABLE 4.8 CALCULATING ALLELE FREQUENCIES OF MARKER

















Lod scores with altered allele frequencies reflecting those present in family P could
then be calculated.
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TABLE 4.9 ANALYSIS OF LOD SCORES WITH EQUAL AND
ADJUSTED ALLELE FREQUENCIES IN FAMILY P
Family Locus Allele freq. Recombination fraction (0)
0.00 0.01 0.05 0.10 0.20 0.30 0.40 0.50
P D9S315 equal -11.86 -3.79 -1.17 -0.08 0.72 0.81 0.54 0.00
P D9S315 adjusted -11.61 -3.54 -1.14 0.09 0.79 0.85 0.55 0.00
P D9S61 equal -6.27 -2.28 -0.34 0.67 1.27 1.17 0.71 0.00
P D9S61 adjusted -6.69 -2.62 -0.45 0.53 1.13 1.05 0.63 0.00
No significant difference was found between lod scores obtained using equal and
adjusted allele frequencies.
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TABLE 4.10 TWO POINT LOD SCORES FOR MARKERS ADJACENT
TO ALK1 IN FAMILY V AND FAMILY T
Family V
Locus Recombination fraction (0)
0.00 0.01 0.05 0.10 0.20 0.30 0.40 0.50
D12S347 -0.04 -0.02 0.03 0.65 0.07 0.05 0.01 0.00
D12S368 1.48 1.45 1.33 1.17 0.81 0.43 0.11 0.00
Family T
Locus Recombination fraction (0)
0.00 0.01 0.05 o• o 0.20 0.30 0.40 0.50
D12S339 -6.25 -1.82 -0.97 -0.58 -0.23 -0.08 -0.02 0.00
D12S347 0.49 0.47 0.43 0.37 0.24 0.12 0.03 0.00
D12S368 -5.98 -1.31 -0.51 -0.19 0.03 0.05 0.02 0.00
Lod scores were calculated at different recombination fractions.
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The numbered family members are the ones which were assessed clinically. Affected individuals are
indicated by black symbols, unaffected by white symbols, and those with unknown diagnosis by grey
symbols. Squares represent males, circles represent females, and a slashed symbol indicates a
deceased individual.
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<o 00 o> O t- co N-
<DJ C\l
CQ
T— co co CO co
CO CO CO 5: CO CO -J CO CO
CD CD >< CD CO CD CD OQ CD CD
Q Q I Q CD QQ Q Q
/ I /r
3 3 7 7 5 21 7 7 8 /- /~9 q tel.
The position ofendoglin relative to flanking markers. Endoglin lies in a 2
centiMorgan (cM) interval between D9S60 and D9S61. The relative positions of
endoglin and AK1 have not been resolved. Distances in the upper part of the
diagram, within the 2 cM region, are physical distances in megabases (Mb).
Distances in the lower part of the diagram, showing the position of the D9S60-D9S61
interval relative to other markers are genetic distances in centiMorgans. They are
represented by the numbers below the horizontal line.
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FIGURE 4.3 TWO POINT AND MULTIPOINT LOD SCORES
SPANNING THE ENDOGLIN LOCUS IN FAMILY S
A: Two point lod scores
Locus Recombination fraction (0)
0.00 0.01 0.05 0.10 0.20 0.30 0.40 0.50
D9S60 -16.67 -8.99 -5.38 -3.52 -1.72 -0.79 -0.26 0.00
D9S315 -16.07 -7.67 -4.93 -3.21 -1.57 -0.72 -0.25 0.00
D9S61 -10.33 -5.58 -2.88 -1.74 -0.74 -0.31 -0.11 0.00
B: Multipoint lod scores
Data obtained using GENEHUNTER via HGMP.
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lo V- o> N. oo LO
M- co lO oo CO CM
00 CO 00 CO CO co CO
CO CO CO CO CO CO CO
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V- T— T— T— T—
Q Q Q Q Q Q Q
/I1 1 7 3 2 I 1 3 //-12 q tel.
h H H
Position ofALK1 relative to flanking markers. The numbers below the horizontal
line are the genetic distances in centiMorgans. The probable ALK1 site is indicated
by a solid black line, with possible extension indicated by a solid grey bar139 The
broken line indicates one of the original intervals 138 which has now been
revised!39.
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FIGURE 4.5 TWO POINT AND MULTIPOINT LOD SCORES
SPANNING THE ALK1 LOCUS IN FAMILY S
A: Two point lod scores
Locus Recombination fraction (0)
0.00 0.01 0.05 0.10 0.20 0.30 0.40 0.50
D12S331 -4.81 -4.76 -3.39 -2.26 -1.17 -0.59 -0.23 0.00
D12S85 -4.67 -4.64 -4.57 -4.19 -2.39 -1.25 -0.50 0.00
D12S347 -9.07 -5.14 -4.60 -3.89 -2.16 -1.14 -0.47 0.00
D12S368 -5.27 -1.67 -0.97 -0.68 -0.39 -0.22 -0.10 0.00
D12S325 -8.78 -4.84 -4.34 -4.00 -2.38 -1.29 -0.55 0.00
Lod scores were calculated at different recombination fractions.












D12S85 X \ D12S325
D12S347 D12S368
Data obtained using GENEHUNTER via HGMP.
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FIGURE 4.6 LIMITED HAPLOTYPE ANALYSES OF
CHROMOSOME 9 AND 12 MARKERS IN FAMILY S
W LJ w
III.2 I II.3 I II.2 I
/■ \ pp c \
D12S331 4 3 4
D9S60 2 3 2 7 D12S85 3 1 8
D9S315 4 6 2 2 D12S347 3 5 2
D9S61 3 9 3 9 D12S368 6 6 6
D12S325 9 3 3
PP V W w k 7











D9S60 2 3 1 3
D9S315 2 6 5 5


































































VI. 1 VI. 1
D12S331 6 4
D9S60 1 1 D12S85 2 8
D9S315 6 5 D12S347 5 4
D9S61 6 2 D12S368 3 5
D12S325 9 1
w w w
D C D C
The analyses are limited to a section of the family S pedigree which includes the two
PAVM individuals (V.3 and V.4). The pedigree shown on the left displays markers
spanning endoglin. In affected individuals V.3, V.4, and VI. 1 all haplotypes (B, C,
and D) are derived from unaffected spouses. The pedigree on the right shows
markers spanning ALKJ. In affected individuals V.3, V.4, and VI. 1 all haplotypes
(B, C, and D) are derived from unaffected spouses. There is a recombination event
in V.4 between D12S85 and D12S347.
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FIGURE 4.7 FAMILY TREE OF FAMILY P
The numbered family members are the ones which were assessed clinically.
Affected individuals are indicated by black symbols, unaffected by white symbols,
and those with unknown diagnosis by grey symbols. Squares represent males, circles
represent females, and a slashed symbol indicates a deceased individual.
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The analyses are limited to a section of the family P
pedigree. Simwalk 2 indicates that there are 3
possible haplotype solutions for these alleles and
therefore no suggestion of chromosomal assignment
is made.
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FIGURE 4.9 FAMILY TREE OF FAMILY V AND FAMILY T
Family V
Family T
The numbered family members are the ones which were assessed clinically.
Affected individuals are indicated by black symbols, unaffected by white symbols,
and those with unknown diagnosis by grey symbols. Squares represent males, circles
represent females, and a slashed symbol indicates a deceased individual. Individual
III. 1 from family V and individual III.4 from family T had proven PAVMs.
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5. DISCUSSION
This work has shown that a two base pair CA deletion polymorphism, with allele
frequency of 9% in the UK population, occurs just over 2 kb upstream of the
endoglin promoter. No polymorphisms or mutations have been found in the endoglin
promoter in the HHT families studied.
The work has also shown that an HHT family is unlinked to the two known genes,
endoglin and ALK1, indicating that at least a third gene exists for HHT. Moreover it
has shown that PAVMs occur in the family linked to this third gene and also occur in
an ULK/-linked family.




A number of important clinical features have been highlighted by the work on
families S and P. Family S member V.4 demonstrated that pregnancy can precipitate
the onset ofHHT manifestations. It is unknown whether family P member V.3's
PAVMs were present prior to her pregnancy but family S member V.4 demonstrates
that pregnancy can precipitate symptomatic PAVMs. The difficulty in diagnosing
PAVMs during pregnancy, due to hypoxaemia being masked, is shown by individual
V.3 from family P who had saturations of 98% supine, 97% erect during pregnancy
but of 94/95% supine, 93/92% erect after delivery. The tendency for pregnancy to
exacerbate HHT manifestations has been demonstrated by the deterioration of a
telangiectatic lesion of the thumb in family P member V.3 during pregnancy, which
improved after delivery of her child. It is not clear the extent to which
haemodynamic changes or the very high oestrogen stated 131 132 contribute to the
exacerbating effect of pregnancy on HHT manifestations.
5.1.1.1. PAVM RESCREENING
It can be seen from the discussion on pregnancy that rescreening for PAVMs is
critical following pregnancy. Family P members V.5, VI. 1, and VI.3 in whom
pregnancy has obviously not occurred, have also shown that PAVMs have possibly
developed since screening 6 years previously. This emphasises the need for
rescreening all HHT patients. Family S member V.3 demonstrates that rescreening
for PAVMs should be performed in patients with previously embolised PAVMs
since his had possibly redeveloped.
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The importance for rescreening for the HHT phenotype is highlighted by the work as
5 new diagnoses were made in individuals assessed 6 years previously. As age-
related penetrance occurs in this disease the probability of becoming affected
decreases with age, but should never be completely overlooked.
5.1.2. MICROSCOPIC PAVMS
Individual V.4 from family S demonstrates a case ofmicroscopic PAVMs. Their
clinical significance is under debate both in terms of their possible interference with
gas exchange, and the possibility of paradoxical embolism occurring through
themes. As they may allow gas exchange, and so may lead to underestimation of the
shunt using the 100% inspired oxygen breathing method 1 '9, technetium scanning
may be more appropriate in these cases. Individual V.4's oximetry would suggest
otherwise. Her frequent dizzy spells, possibly indicative ofTIAs, would suggest that
paradoxical embolism can occur.
If these microscopic PAVMs are clinically relevant then they must be detected.
Nearly 50% of patients in whom contrast echocardiography is suggestive ofPAVMs
will not have PAVMs demonstrated at pulmonary angiography! 11. While it is not
clear whether these patients have microscopic PAVMs or whether they represent a
subgroup of normal appearances^ there is an increasingly prevalent view that
contrast echocardiography may represent an appropriate first line screen for
PAVMs111. V.4's case suggests that contrast echocardiography may not detect all
PAVMs however, since the contrast echocardiography was negative on the same day
that her right to left shunt was quantified by technetium scanning as 7.8%. It would
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support the view that contrast echocardiography should be used in conjunction with
other investigations.
It could be argued that it is pointless detecting these microscopic PAVMs, even if
they are clinically relevant, since embolisation is usually not possible. It is important
however if they are clinically relevant for these patients to take prophylactic
antibiotics before undergoing procedures that could cause bacteraemia^5. It is also
vital to detect these patients so that they can be studied further, thus increasing our
knowledge of the clinical implications and course of their disease.
Page 144
5.2. MOLECULAR ISSUES
5.2.1. THE IMPORTANCE OF FINDING A POLYMORPHISM CLOSE TO
THE ENDOGLIN PROMOTER
As discussed in Section 1.5.6 a polymorphism is useful as a tool for association and
linkage studies. The polymorphism found just over 2 kb upstream of the endoglin
promoter was detected prior to the publication of the human SNP map221. Although
of less importance now, at the time this finding was useful because the
polymorphism has a reasonably high allele frequency, and there were then only
seven known polymorphisms^ 235 236 jn the endoglin gene, the closest to the
promoter being in exon 1.
5.2.1.1. SHOULD THE ENDOGLINPROMOTER BE SCREENED FOR HHT
MUTATIONS?
Since no mutations or even polymorphisms were seen in the endoglin promoter
region in the eight HHT families screened in this work, the question arises as to
whether or not the promoter should be screened in other HHT families. It remains
possible that promoter mutations could account for disease in other endoglinAmked
families given that they have null alleles. Moreover polymorphisms in the promoter
regions ofmany other genes lead to disease. For instance in the promoter region of
the Factor VII gene encoding a key component of the coagulation cascade,
polymorphisms have been found which influence the binding properties of nuclear
proteins and thereby alter the transcription rate of the gene237 \ further
polymorphism in this promoter has been found to alter factor VII levels and to be
associated with differing risk ofmyocardial infarction amongst patients with an equal
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extent of coronary atherosclerosis, independent of other risk factors238 Similarly
polymorphisms in the protein C promoter region lead to different protein C levels
and to different thrombotic risks239 These promoter polymorphisms are not just
restricted to members of the coagulation cascade. Interestingly a polymorphism in
the TNFa promoter causing increased transcription of the gene has been found to
lead to an increased risk of cerebral malaria independent ofHLA class I and II
variational)
It therefore seems appropriate to continue screening the endoglin promoter region for
polymorphisms in other HHT families which may harbour polymorphisms that are
functional and possibly disease-causing.
5.2.1.2. FUNCTIONAL EFFECTS OF ANY PROMOTER POLYMORPHISM
FOUND
Although it is tempting on finding a sequence variation in the coding or regulatory
regions of the gene to assume this will lead to a functional difference, scientific
rigour is needed to confirm the hypothesis. Where present in an inherited disease,
cosegregation of the variant with the disease in question needs to be demonstrated.
Lack of cosegregation of the promoter polymorphism described previously (see
Section 3.4.2) significantly reduced its likely functional importance.
Direct functional studies can be performed relatively easily by ligating either the
wild-type promoter, or the promoter containing the promoter polymorphism, into
separate reporter vectors containing a promoterless gene, where transcription of the
gene can be assayed in transiently transfected cells. (This approach was used for
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analysis of luciferase gene expression controlled by the wild-type endoglin
promoter, with luciferase activity measured using a luminometer' 33)
Similarly, confirmation of a disruption of function in a gene in which a coding
sequence variation is found supports the hypothesis that the sequence variation is
significant, and may shed light on the molecular mechanism of a particular
pathological process. cDNA containing the wild-type or variant sequence can be
ligated into a vector carrying a strong eukaryotic cell promoter, and either
biochemical studies of the encoded proteins, or studies of downstream effects on cell
function, may be compared. This approach was successfully used to confirm the
haploinsufficient disease mechanism for endoglin in HHT'49^ an(j disruption of
normal endoglin function in ongoing studies in my supervisor's laboratory^ 1.
5.2.1.3. OTHER REGIONS TO BE SCREENED
Although the promoter region and entire coding sequence of endoglin has been
screened without detecting the disease-causing mutation in four endoglin-linked
HHT families, further regions of the gene may contain the disease-causing mutation.
Introns (the first intron in particular) and 3' untranslated regions tend to contain
regulatory elements for many genes, and a testable hypothesis would be that
haploinsufficiency of endoglin could also result due to mutations in these regulatory
elements.
5.2.2. THE IMPORTANCE OF IDENTIFYING THE THIRD GENE
As described in the introduction chapter, endoglin and ALKl are both involved in the
regulation of response to ligands of the TGFp superfamily. It seems reasonable to
speculate that the gene mutated in family S, the family unlinked to endoglin and
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ALK1, may encode another component of the TGF|3 signalling complex or a
downstream effector. Its identification should significantly enhance our
understanding of signalling by TGFP family members which, although increasing,
still has many areas yet to be elucidated.
As discussed in the introduction chapter, the TGFP superfamily is implicated in
many different pathological processes including vascular development, homeostasis,
and repair, and cellular proliferation^ 186 188 189 These are important in a wide
range of disease processes including atherosclerosis, oncogenesis, pulmonary
hypertension and fibrosis in addition to HHT. There are therefore compelling
clinical as well as scientific reasons why understanding the mechanism by which
TGF-P family members act is so important.
The confirmation by this work that at least a third HHT gene exists has precipitated
work to identify the gene. Using genomic DNA of affected and unaffected members
of family S, the family unlinked to endoglin and ALK1, PCR-based analysis of
polymorphic markers in the vicinity of candidate genes selected from the TGFP
superfamily has been performed. No linkage was found to these genes242 and so a
genome-wide search using fluorescently-labelled polymorphic markers with an
average lOcM resolution has been commenced. Over a third of the genome has been
excluded to date. Further details of the findings of this part of the analysis are not
available to me. Any regions in which lod scores are suggestive of linkage in the
initial screen using markers at lOcM intervals will be saturated by analysis of further
polymorphisms in the vicinity. Once a lod score greater than 3.0 is obtained,
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analyses of GenBank (http://www.ncbi.nlm.nih.gov) and Ensembl
(http://www.ensembl.org) databases will be performed to identify potential candidate
genes in the region. This will lead to mutational screening of the suspected gene in
this family by Southern blotting and sequencing ofPCR products from genomic
DNA and cDNA. The genomic DNA analyses will be substantially assisted by the
Ensembl database of genomic DNA sequence which can be scrutinised using short
DNA sequences analogous to Blast searches of the GenBank databases.
5.2.2.1. ELUCIDATION OF THE BIOCHEMICAL ROLE
In this study, the work did not reach the stage of identification of the third gene and
therefore elucidation of its biochemical role. However, as mentioned previously, my
work has precipitated work to identify the third gene and thereafter its biochemical
role. Analyses are first likely to include clarification as to whether or not the mutant
protein is required for the pathogenesis of the disease, by assessment of production
ofmRNA or protein by the mutant allele. A low level of rogue mRNA transcription
is predicted in all cells243 ancj therefore the cDNA of the gene in question is likely to
be amplified by reverse transcriptase PCR (RT-PCR) amplification ofmRNA
isolated from peripheral blood leukocytes or EBV-transformed lymphoblastoid lines
of an affected individual^ Protein analysis requires significantly higher levels of
transcription and production of a stable protein. This is best performed in
overexpression systems by transiently transfecting eukaryotic cells such as Chinese
Hamster Ovary (CHO) cells with the normal (wild type) gene under investigation
and with various mutant constructs of the gene. The effects of the mutant constructs
can then be studied by a number ofbiochemical methods including
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immunoprecipitation with radiolabeled ligands or radiolabeled antibodies to the
encoded protein, Western blot analysis, or flow cytometry if antibodies to the new
gene are available (alternative metabolic labelling methods are also available if
monoclonal antibodies are not available)'46 149 Functional studies can be
performed assessing for general physiological effects such as alterations of cellular
proliferation or migration'89 244^ or effects on specific genes by assessment of the
cellular concentrations of particular mRNA species by Northern blots'89^ or altered
function of a promoter thought likely to be affected by the signalling from the wild-
type protein (analysed using a luciferase reporter plasmid known to be affected by
the protein under investigational). Ultimately, many studies of gene function
progress to assessment of transgenic animals in which the gene has been deleted by
homologous recombination (leading to null or "knock-out" mice), or in which a gene
is overexpressed, a technique applicable to all species as it is not dependent on the
availability of pleuripotential embryonal stem (ES) cells, currently available for mice
onlyl^O 245
5.2.3. PHENOTYPE/ GENOTYPE CORRELATIONS
PAVMs have previously been seen predominantly in endoglin-livked families^ 143
144 This led to the suggestion that a correlation could be made between pulmonary
involvement and genotype!41 142 This work shows that PAVMs also occur in
families linked to ALK1 and at least a third gene. There is therefore no absolute
association between pulmonary involvement and genotype. This has significant
implications for clinical PAVM screening, the importance ofwhich has been
discussed previously. From these data it can be recommended that all HHT patients
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are screened clinically for PAVMs. These data are also important for mutational
screening programmes. Patients with pulmonary involvement, whose underlying
disease gene is unknown, should not be limited to endoglin screening but should
have linkage analysis performed first if family size permits.
Since PAVMs cannot be used as an indicator of genotype, the question arises as to
whether there are any phenotypic differences in HHT manifestation between family
S, the family unlinked to endoglin and ALK1, and other HHT families linked to these
genes. There do not appear to be phenotypic differences. As with other families this
pedigree showed a range of severity of disease. The PAVM clinical presentation and
response to embolisation ofV.3 reflect the majority ofPAVM patients who present
symptomatically. The apparent precipitation of V.4's symptoms and PAVMs by
pregnancy is well recognisedThe incidence of cerebral and hepatic involvement
in this family is unknown as asymptomatic screening for these complications is not
performed routinely in the UK. The geographical and fish tongue seen in IV. 3 could
be coincidental or could be associated with HHT, although it has not been described
previously. It was however also seen in members of family P which has not been
proven to be linked to a third gene. At the moment, therefore, possible phenotypic
indicators of underlying genotype remain elusive.
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5.3. VASCULAR BIOLOGY ISSUES
5.3.1. WHY ARE SOME VESSELS ABNORMAL AND NOT OTHERS?
A fundamental question remains which is why do abnormal vascular structures, in
particular PAVMs, develop? Endoglin and ALK1 are both involved in the TGFP
superfamily which has a role in vasculogenesis and angiogenesis so one might expect
low levels of endoglin or ALK1 in HHT affected individuals to lead to abnormal
vessel morphology. However AVMs and apparently normal vessels in affected
individuals have similar levels of endoglin (and presumably ALK1) so there must be
additional factors leading to AVM formation 164 Altered blood flow and/or
hormonal changes could initiate the process in vessels already susceptible due to
decreased endoglin/ALK1 levels^. Vessel remodelling could then be exacerbated
through a lack of the homeostatic mechanisms normally orchestrated by TGFpU^
It could be that other genetic factors, as yet undetermined, could influence which
vessels develop AVMs 164
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5.4. CONCLUDING REMARKS
Although much is now known about endoglin, and to a lesser extent ALK1, regarding
specific gene mutations and the biochemical actions of the proteins they encode, a
clear understanding of the pathophysiology ofHHT has yet to be achieved.
Identification of a third gene and elucidation of its encoded protein should increase
our knowledge of the actions of the TGFp superfamily, but may not immediately
improve our understanding ofwhy disruption of these actions can lead to abnormal
vascular structures. It is vital that research continues in this fascinating area to
improve our knowledge of the pathophysiology of both HHT and also the many other
diseases in which the TGFp superfamily is clearly involved.
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5.5. FURTHER WORK
The results ofmy work highlight a number of areas requiring further study, several
ofwhich have already commenced:
5.5.1. CLINICAL
• From a clinical point of view, further study of patients with microscopic PAVMs
is important to determine their clinical significance, diagnosis, and possible
treatment. The risks versus the benefits of screening and treating asymptomatic
cerebral AVMs needs to be determined so that a decision can be made on
screening for these CAVMs246 Continuing clinical assessment ofHHT families
is vital ifwe are to identify any phenotypic indicators of genotype.
5.5.2. MOLECULAR
• The endoglin promoter region should be screened in further endoglin-Mrked
HHT families: (I have been asked by a Canadian group, currently screening the
endoglin gene for mutations, to supply them with the primer sequences and
screening methods used in this study.)
• Regions of the first intron (unlikely to be in its entirety as the intron is over 12kb
long) and the area 3' to exon 14 should be screened in the families studied in this
work, and further families in which the endoglin mutation is elusive.
• The confirmation of the existence of at least a third HHT gene necessitates the
identification of the gene. Once the gene is identified this will precipitate further
work to elucidate its biochemical role. Since this thesis was first written this
work has commenced, first by analysing for linkage to candidate genes from the
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TGFp superfamily and then by a genome-wide search using conventional linkage
techniques242
5.5.3. VASCULAR BIOLOGY
• More generally, further work is required to identify the endoglin and ALK1
ligand and the particular TGFP superfamily ligands involved in HHT. The
mechanism by which the TGFp superfamily leads to the abnormal vascular
structures ofFIHT, and indeed to the other many pathological processes with
which it is involved, must be elucidated ifmolecular therapies are going to be
offered in the future.
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APPENDIX B - RECIPES
10x Tris Borate EDTA (TBE)
108 grams(g) Tris base
55g Boric acid
40mls 0.5M EDTA pH 8.0
Double distilled water to one litre
Phosphate Buffered Solution (PBS)
1 tablet (made by oxoid) to lOOmls double distilled water
Extraction Buffer
70mls double distilled water
5mls 2M Tris pH 8.0
20mls 0.5M EDTA
Genomic Tris EDTA (GTE)
99.3mls double distilled water
0.5mls 2M Tris pH 8.0
0.2mls 0.5M EDTA
3M Sodium Acetate
123g anhydrous sodium acetate
800mls double distilled water- pH to 5.2 with acetic acid then made up to 1 litre
with double distilled water
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Agarose Gel Loading Buffer
15mls glycerol
35mls double distilled water
A few grains ofbromophenol blue
Denaturing Polvacrvlamide Gel Loading Buffer
lOmls formamide
lOmg xylene cyanol FF
lOmg bromophenol blue
200pl 0.5M EDTA pH 8.0
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GW1 TCC.CAA TCT.CTT.CCT.TCC.TCC.ATG.A 74
GW2 GCC.AGA.GAC.CAG.GGT.TAA.AGT.GAA A 74
GW3 CTG.GGT.TCA.AAT.CCG ATT CTG.CT 68
GW4 GTC.CAA.GGT.CTC.ATG.GCT.AGG.AG 72
GW5 TCT.TCC TTC.CTC.CAT.GAG.GTG.T 66
GW6 TTA.AAG.TGA.AAG.AGT.CAG.CCC.AGT 68
GW7 GCT.GGA.GTT.GCT.GTC.CGA.AGG.A 70
GW 8 CTC.CAA.TGG.ATG.GCA.GTG.ACA 64
GW 9 CTG.TTA.GGG TGA TTG.TTT.TCA.TCT 66
GW 10 CTG.TCC.CCA.TCC.ACG.TTG.TAA.ACA 72
GW 11 GCC.CCA.TGT.CAA.CTG.CAC.TTA.GTA 72
GW 12 CAG.GCT.CTA.GGC.TTG.TCT.CCC.CAA 76
GW 13 TTC.AGT.TTT.CCT.GCC TGT.TAG.GCA 70
GW 14 GAG.GGT CAG.GAG.AAG.TGG.ACA CAG.GGA 86
GW 15 GCG.CAG ATG.AAG.GCT.GTG.GTA.TGA 74
GW 16 GTT.GTA.AAC.AAG.ACC.CAA.TGG.ATT 66
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APPENDIX D - PRIMERS FOR ENDOGLIN LINKAGE
Name Sense primer Antisense primer
D9S261 AGG.CTG.TGG.TAT.TCC.CAT.T AGG.TTG.CAA.GAT GTT.TGA.TT
D9S289 TGC.ATT.AGA.AAA.CCT.TCC.A CCC.AGC.CTA.TTT.GCAT
HXB ATA.GCC.AAA.GAGAGG.TGC.ee AGA.GCC.CTT.CTG.TCT.TCT CC
D9S195 AGC.TCA.GCA.CGG.AGG.G AGG.GCA.GGT.TCC.TAC.AAA
GSN CAG.CCA.GCT.TTG.GAG ACA.AC TCG.CAA.GCA TAT.GAC.TGT.AA
D9S60 TTC.TGG.GAA GCC.TTC.CCT.GA TGA.ATG.CCA.CTA.TTC.ATG ATG
D9S315 TTC.TCT.TTG.TCA.TCA CTT.TTG.G CTC.AAA.GTA.ACA.CGC.CTG.TG
D9S61 TGA.GAG.ACC.CTC.ACT.CCC.TA ACA.GAT.GTC.TGT.AGT.CGG TC
ABL TTT.ACA.CCT.TCA.CCC.AGA.GA GGC.TGT.GTT.CAG.TTA.AAC.G
D9S66 CAG ACC.AGG.AAT.GCA.TGA.AG CAC.GGG.CAC.ACA.TGT.ATG.C
D9S67 CCA.GGC TGT.TTA.CTT.TGG.CA GCC.GGG.AGG ATG ACA.TGT.A





D9S261 0.63 90-104 49
D9S289 0.75 75-87 43
HXB 0.79 107-121 57
D9S195 0.74 204-240 51
GSN 0.70 111-130 51
D9S60 0.81 136-154 53
D9S315 - -110 55
D9S61 0.80 112-150 55
ABL 0.67 90-117 51
D9S66 0.79 109-135 55
D9S67 0.67 71-113 55
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APPENDIX E - PRIMERS FOR ALK1 LINKAGE
Name Sense primer Antisense primer
D12S331 TAA.CAT.TTA.TTC.ATC.TCC.ATA.CTG.A ACA.TGT.AAG.AGA.GNA.AGT.TTA.CAA.A
D12S85 GCA.CCT.CTC.ACT.CCA.TTA CA AAA.TGA.AAG.TCA.AGG.GGA.AC
D12S339 TCA.GGG.TTT.GAG.ACT.NGC.C GTC.ACG.CCT.GGC.TAG.TGT
D12S347 ITT TIT GAG.TCC.AGG.CCA CCA.GCA GAG.TTT TGC.CTT.T
D12S368 GCA.ACA.CCT.TTG.TGA.TGA.AAA.T AGT.CTG.CAC.AGC.CTG.TCC
D12S325 GGG.CAC.TAT.GGT GTC.TTC.A AGG.GCA.TTG.TCT TAC.TGA.CTG





D12S331 0.61 175-181 59
D12S85 0.67 105-125 51
D12S339 0.85 257-277 53
D12S347 0.62 96-114 50
D12S368 0.81 200-216 56
D12S325 0.66 209-229 53
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